UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 10-Q
____________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                      
Commission File No.: 001-16753

amn-20200930_g1.jpg
AMN HEALTHCARE SERVICES, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware06-1500476
(State or Other Jurisdiction of

Incorporation or Organization)
(I.R.S. Employer

Identification No.)
12400 High Bluff Drive8840 Cypress Waters BoulevardSuite 100300
San DiegoDallasCaliforniaTexas9213075019
(Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866(866) 871-8519
____________________

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par valueAMNNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x  No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  x No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer  Non-accelerated filer
Smaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).  Yes  ☐  No  x
As of October 30, 2019,November 4, 2020, there were 46,711,15547,030,832 shares of common stock, $0.01 par value, outstanding.




TABLE OF CONTENTS
 
Item Page
PART I - FINANCIAL INFORMATION
1.
2.
3.
4.
PART II - OTHER INFORMATION
1.
1A.
2.
3.
4.
5.
6.


Item Page
   
 PART I - FINANCIAL INFORMATION 
   
1.
 
 
 
 
 
2.
3.
4.
   
 PART II - OTHER INFORMATION 
   
   
1.
1A.
2.
3.
4.
5.
6.
 





PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

AMN HEALTHCARE SERVICES, INC.
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited and in thousands, except par value)
 September 30, 2019 December 31, 2018
ASSETS   
Current assets:   
Cash and cash equivalents$40,748
 $13,856
Accounts receivable, net of allowances of $11,324 and $10,560 at September 30, 2019 and December 31, 2018, respectively354,742
 365,871
Accounts receivable, subcontractor62,752
 50,143
Prepaid expenses11,325
 12,409
Other current assets37,365
 39,887
Total current assets506,932
 482,166
Restricted cash, cash equivalents and investments59,165
 59,331
Fixed assets, net of accumulated depreciation of $127,005 and $114,413 at September 30, 2019 and December 31, 2018, respectively100,199
 90,419
Operating lease right-of-use assets92,257
 
Other assets115,482
 96,152
Goodwill586,611
 438,506
Intangible assets, net of accumulated amortization of $140,342 and $114,924 at September 30, 2019 and December 31, 2018, respectively400,428
 326,147
Total assets$1,861,074
 $1,492,721
LIABILITIES AND STOCKHOLDERS’ EQUITY   
Current liabilities:   
Accounts payable and accrued expenses$139,505
 $149,603
Accrued compensation and benefits157,950
 135,059
Current portion of notes payable3,750
 
Current portion of operating lease liabilities13,387
 
Deferred revenue11,227
 12,365
Other current liabilities18,090
 10,243
Total current liabilities343,909
 307,270
Revolving credit facility146,000
 120,000
Notes payable, less unamortized fees465,899
 320,607
Deferred income taxes, net46,356
 27,326
Operating lease liabilities94,150
 
Other long-term liabilities59,656
 78,528
Total liabilities1,155,970
 853,731
Commitments and contingencies


 


Stockholders’ equity:   
Preferred stock, $0.01 par value; 10,000 shares authorized; none issued and outstanding at September 30, 2019 and December 31, 2018
 
Common stock, $0.01 par value; 200,000 shares authorized; 49,271 issued and 46,710 outstanding at September 30, 2019 and 48,809 issued and 46,643 outstanding at December 31, 2018493
 488
Additional paid-in capital451,096
 452,730
Treasury stock, at cost (2,561 and 2,166 shares at September 30, 2019 and December 31, 2018, respectively)(119,143) (100,438)
Retained earnings372,565
 286,059
Accumulated other comprehensive income93
 151
Total stockholders’ equity705,104
 638,990
Total liabilities and stockholders’ equity$1,861,074
 $1,492,721
September 30, 2020December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents$58,419 $82,985 
Accounts receivable, net of allowances of $8,511 and $3,332 at September 30, 2020 and December 31, 2019, respectively352,746 352,685 
Accounts receivable, subcontractor56,300 72,714 
Prepaid expenses15,647 11,669 
Other current assets30,591 40,446 
Total current assets513,703 560,499 
Restricted cash, cash equivalents and investments60,898 62,170 
Fixed assets, net of accumulated depreciation of $153,390 and $132,900 at September 30, 2020 and December 31, 2019, respectively112,752 104,832 
Operating lease right-of-use assets81,082 89,866 
Other assets125,831 120,254 
Goodwill869,941 595,551 
Intangible assets, net of accumulated amortization of $199,488 and $151,417 at September 30, 2020 and December 31, 2019, respectively580,658 398,474 
Total assets$2,344,865 $1,931,646 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses$152,935 $156,140 
Accrued compensation and benefits184,736 170,932 
Current portion of notes payable9,375 
Current portion of operating lease liabilities15,338 13,943 
Deferred revenue11,900 11,788 
Other current liabilities11,884 25,302 
Total current liabilities386,168 378,105 
Revolving credit facility40,000 
Notes payable, net of unamortized fees and premium854,533 617,159 
Deferred income taxes, net79,681 46,618 
Operating lease liabilities81,674 91,209 
Other long-term liabilities95,736 61,813 
Total liabilities1,537,792 1,194,904 
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 10,000 shares authorized; NaN issued and outstanding at September 30, 2020 and December 31, 2019
Common stock, $0.01 par value; 200,000 shares authorized; 49,550 issued and 46,989 outstanding at September 30, 2020 and 49,283 issued and 46,722 outstanding at December 31, 2019495 493 
Additional paid-in capital465,438 455,193 
Treasury stock, at cost; 2,561 shares at September 30, 2020 and December 31, 2019(119,143)(119,143)
Retained earnings460,250 400,047 
Accumulated other comprehensive income33 152 
Total stockholders’ equity807,073 736,742 
Total liabilities and stockholders’ equity$2,344,865 $1,931,646 

See accompanying notes to unaudited condensed consolidated financial statements.
1


AMN HEALTHCARE SERVICES, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited and in thousands, except per share amounts)
 
Three Months Ended September 30, Nine Months Ended September 30, Three Months Ended September 30,Nine Months Ended September 30,
2019 2018 2019 2018 2020201920202019
Revenue$567,597
 $526,842
 $1,635,215
 $1,607,439
Revenue$551,631 $567,597 $1,762,443 $1,635,215 
Cost of revenue377,566
 351,695
 1,088,883
 1,083,512
Cost of revenue366,998 377,566 1,178,204 1,088,883 
Gross profit190,031
 175,147
 546,332
 523,927
Gross profit184,633 190,031 584,239 546,332 
Operating expenses:       Operating expenses:
Selling, general and administrative133,207
 121,216
 374,872
 341,488
Selling, general and administrative111,235 133,207 394,537 374,872 
Depreciation and amortization17,085
 11,296
 41,513
 29,788
Depreciation and amortization26,936 17,085 69,096 41,513 
Total operating expenses150,292
 132,512
 416,385
 371,276
Total operating expenses138,171 150,292 463,633 416,385 
Income from operations39,739
 42,635
 129,947
 152,651
Income from operations46,462 39,739 120,606 129,947 
Interest expense, net, and other7,830
 4,649
 19,568
 16,360
Interest expense, net, and other12,564 7,830 35,061 19,568 
Income before income taxes31,909
 37,986
 110,379
 136,291
Income before income taxes33,898 31,909 85,545 110,379 
Income tax expense8,394
 10,068
 23,873
 30,163
Income tax expense7,831 8,394 24,188 23,873 
Net income$23,515
 $27,918
 $86,506
 $106,128
Net income$26,067 $23,515 $61,357 $86,506 
       
Other comprehensive income (loss):       Other comprehensive income (loss):
Foreign currency translation and other132
 133
 (58) 205
Foreign currency translation and other(14)132 (119)(58)
Other comprehensive income (loss)132
 133
 (58) 205
Other comprehensive income (loss)(14)132 (119)(58)
       
Comprehensive income$23,647
 $28,051
 $86,448
 $106,333
Comprehensive income$26,053 $23,647 $61,238 $86,448 
       
Net income per common share:       Net income per common share:
Basic$0.50
 $0.59
 $1.85
 $2.23
Basic$0.55 $0.50 $1.29 $1.85 
Diluted$0.49
 $0.58
 $1.82
 $2.17
Diluted$0.55 $0.49 $1.29 $1.82 
Weighted average common shares outstanding:       Weighted average common shares outstanding:
Basic46,677
 47,286
 46,701
 47,556
Basic47,476 46,677 47,406 46,701 
Diluted47,607
 48,529
 47,600
 48,859
Diluted47,676 47,607 47,647 47,600 
       
 
See accompanying notes to unaudited condensed consolidated financial statements.

2


AMN HEALTHCARE SERVICES, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited and in thousands)
 Common StockAdditional
Paid-in
Capital
Treasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total
 SharesAmountSharesAmount
Balance, December 31, 201848,809 $488 $452,730 (2,166)$(100,438)$286,059 $151 $638,990 
Repurchase of common stock into treasury— — — (378)(17,930)— — (17,930)
Equity awards vested and exercised, net of shares withheld for payroll taxes313 (10,284)— — — — (10,281)
Share-based compensation— — 5,186 — — — — 5,186 
Comprehensive income (loss)— — — — — 34,122 (101)34,021 
Balance, March 31, 201949,122 $491 $447,632 (2,544)$(118,368)$320,181 $50 $649,986 
Repurchase of common stock into treasury— — — (17)(775)— — (775)
Equity awards vested and exercised, net of shares withheld for payroll taxes101 (1,254)— — — — (1,253)
Share-based compensation— — 3,702 — — — — 3,702 
Comprehensive income (loss)— — — — — 28,869 (89)28,780 
Balance, June 30, 201949,223 $492 $450,080 (2,561)$(119,143)$349,050 $(39)$680,440 
Equity awards vested and exercised, net of shares withheld for payroll taxes48 (1,809)— — — — (1,808)
Share-based compensation— — 2,825 — — — — 2,825 
Comprehensive income— — — — — 23,515 132 23,647 
Balance, September 30, 201949,271 $493 $451,096 (2,561)$(119,143)$372,565 $93 $705,104 


3


 Common Stock 
Additional
Paid-in
Capital
 Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Total
 Shares Amount Shares Amount 
Balance, December 31, 201748,411
 $484
 $453,351
 (930) $(33,425) $142,229
 $(112) $562,527
Equity awards vested and exercised, net of shares withheld for payroll taxes349
 4
 (10,930) 
 
 
 
 (10,926)
Cumulative-effect adjustment from adoption of the new revenue recognition standard
 
 
 
 
 2,089
 
 2,089
Share-based compensation
 
 2,864
 
 
 
 
 2,864
Comprehensive income (loss)
 
 
 
 
 42,681
 (19) 42,662
Balance, March 31, 201848,760
 $488
 $445,285
 (930) $(33,425) $186,999
 $(131) $599,216
Repurchase of common stock into treasury
 
 
 (385) (20,891) 
 
 (20,891)
Equity awards vested and exercised, net of shares withheld for payroll taxes47
 
 (482) 
 
 
 
 (482)
Share-based compensation
 
 3,281
 
 
 
 
 3,281
Comprehensive income
 
 
 
 
 35,529
 91
 35,620
Balance, June 30, 201848,807
 $488
 $448,084
 (1,315) $(54,316) $222,528
 $(40) $616,744
Repurchase of common stock into treasury
 
 
 (580) (31,859) 
 
 (31,859)
Equity awards vested and exercised, net of shares withheld for payroll taxes2
 
 (25) 
 
 
 
 (25)
Share-based compensation
 
 1,809
 
 
 
 
 1,809
Comprehensive income
 
 
 
 
 27,918
 133
 28,051
Balance, September 30, 201848,809
 $488
 $449,868
 (1,895) $(86,175) $250,446
 $93
 $614,720
 Common StockAdditional
Paid-in
Capital
Treasury StockRetained EarningsAccumulated Other Comprehensive IncomeTotal
 SharesAmountSharesAmount
Balance, December 31, 201949,283 $493 $455,193 (2,561)$(119,143)$400,047 $152 $736,742 
Equity awards vested and exercised, net of shares withheld for payroll taxes140 (4,354)— — — — (4,353)
Cumulative-effect adjustment from adoption of the credit loss standard, net of tax— — — — — (1,154)— (1,154)
Share-based compensation— — 4,927 — — — — 4,927 
Comprehensive income (loss)— — — — — 12,965 (47)12,918 
Balance, March 31, 202049,423 $494 $455,766 (2,561)$(119,143)$411,858 $105 $749,080 
Equity awards vested and exercised, net of shares withheld for payroll taxes119 (289)— — — — (288)
Share-based compensation— — 6,347 — — — — 6,347 
Comprehensive income (loss)— — — — — 22,325 (58)22,267 
Balance, June 30, 202049,542 $495 $461,824 (2,561)$(119,143)$434,183 $47 $777,406 
Equity awards vested and exercised, net of shares withheld for payroll taxes— (158)— — — — (158)
Share-based compensation— — 3,772 — — — — 3,772 
Comprehensive income (loss)— — — — — 26,067 (14)26,053 
Balance, September 30, 202049,550 $495 $465,438 (2,561)$(119,143)$460,250 $33 $807,073 


 Common Stock 
Additional
Paid-in
Capital
 Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Total
 Shares Amount Shares Amount 
Balance, December 31, 201848,809
 $488
 $452,730
 (2,166) $(100,438) $286,059
 $151
 $638,990
Repurchase of common stock into treasury
 
 
 (378) (17,930) 
 
 (17,930)
Equity awards vested and exercised, net of shares withheld for payroll taxes313
 3
 (10,284) 
 
 
 
 (10,281)
Share-based compensation
 
 5,186
 
 
 
 
 5,186
Comprehensive income (loss)
 
 
 
 
 34,122
 (101) 34,021
Balance, March 31, 201949,122
 $491
 $447,632
 (2,544) $(118,368) $320,181
 $50
 $649,986
Repurchase of common stock into treasury
 
 
 (17) (775) 
 
 (775)
Equity awards vested and exercised, net of shares withheld for payroll taxes101
 1
 (1,254) 
 
 
 
 (1,253)
Share-based compensation
 
 3,702
 
 
 
 
 3,702
Comprehensive income (loss)
 
 
 
 
 28,869
 (89) 28,780
Balance, June 30, 201949,223
 $492
 $450,080
 (2,561) $(119,143) $349,050
 $(39) $680,440
Equity awards vested and exercised, net of shares withheld for payroll taxes48
 1
 (1,809) 
 
 
 
 (1,808)
Share-based compensation
 
 2,825
 
 
 
 
 2,825
Comprehensive income
 
 
 
 
 23,515
 132
 23,647
Balance, September 30, 201949,271
 $493
 $451,096
 (2,561) $(119,143) $372,565
 $93
 $705,104

See accompanying notes to unaudited condensed consolidated financial statements.

4


AMN HEALTHCARE SERVICES, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited and in thousands)
Nine Months Ended September 30, Nine Months Ended September 30,
2019 2018 20202019
Cash flows from operating activities:   Cash flows from operating activities:
Net income$86,506
 $106,128
Net income$61,357 $86,506 
Adjustments to reconcile net income to net cash provided by operating activities:   Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization41,513
 29,788
Depreciation and amortization70,077 41,513 
Non-cash interest expense and other1,816
 591
Non-cash interest expense and other3,727 1,816 
Write-off of fees on the prior credit facilities
 574
Write-off of fees on credit facilitiesWrite-off of fees on credit facilities1,773 
Change in fair value of contingent consideration2,283
 (1,307)Change in fair value of contingent consideration(1,700)2,283 
Increase in allowances for doubtful accounts and sales credits6,809
 6,240
Increase in allowance for credit losses and sales creditsIncrease in allowance for credit losses and sales credits7,580 6,809 
Provision for deferred income taxes(3,700) (2,384)Provision for deferred income taxes(17,923)(3,700)
Share-based compensation11,713
 7,954
Share-based compensation15,046 11,713 
Loss on disposal or sale of fixed assets449
 40
Loss on disposal or sale of fixed assets3,664 449 
Amortization of discount on investments(276) (78)Amortization of discount on investments(96)(276)
Net loss on deferred compensation balancesNet loss on deferred compensation balances798 
Non-cash lease expense(1) 
Non-cash lease expense244 (1)
Changes in assets and liabilities, net of effects from acquisitions:   Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable25,146
 743
Accounts receivable15,151 25,146 
Accounts receivable, subcontractor(12,610) (3,879)Accounts receivable, subcontractor16,414 (12,610)
Income taxes receivable(3,401) 12,997
Income taxes receivable6,157 (3,401)
Prepaid expenses1,118
 2,334
Prepaid expenses(3,361)1,118 
Other current assets1,332
 446
Other current assets2,977 1,332 
Other assets(8,790) (1,019)Other assets3,378 (8,790)
Accounts payable and accrued expenses(14,277) 7,311
Accounts payable and accrued expenses(5,484)(14,277)
Accrued compensation and benefits19,787
 11,014
Accrued compensation and benefits7,630 19,787 
Other liabilities(7,273) (10,423)Other liabilities29,592 (7,273)
Deferred revenue(2,038) 1,062
Deferred revenue(32)(2,038)
Restricted investments balance99
 (86)Restricted investments balance12 99 
Net cash provided by operating activities146,205
 168,046
Net cash provided by operating activities216,981 146,205 
   
Cash flows from investing activities:   Cash flows from investing activities:
Purchase and development of fixed assets(24,776) (23,922)Purchase and development of fixed assets(27,357)(24,776)
Purchase of investments(16,759) (27,185)Purchase of investments(37,418)(16,759)
Proceeds from maturity of investments28,635
 10,400
Proceeds from maturity of investments21,500 28,635 
Payments to fund deferred compensation plan(11,364) (7,800)Payments to fund deferred compensation plan(7,171)(11,364)
Equity investment
 (4,600)
Cash paid for acquisitions, net of cash received(228,222) (217,361)
Proceeds from sale of equity investmentProceeds from sale of equity investment303 
Purchase of convertible promissory notesPurchase of convertible promissory notes(490)
Cash paid for acquisitions, net of cash and restricted cash receivedCash paid for acquisitions, net of cash and restricted cash received(476,491)(228,222)
Cash paid for other intangibles(1,120) (1,180)Cash paid for other intangibles(1,400)(1,120)
Cash received for working capital adjustments for prior year acquisitionsCash received for working capital adjustments for prior year acquisitions66 
Net cash used in investing activities(253,606) (271,648)Net cash used in investing activities(528,458)(253,606)
5



 Nine Months Ended September 30,
 20202019
Cash flows from financing activities:
Payments on term loans(203,125)(938)
Proceeds from term loans250,000 150,000 
Payments on revolving credit facility(205,000)(75,000)
Proceeds from revolving credit facility245,000 101,000 
Proceeds from senior notes202,000 
Repurchase of common stock(18,705)
Payment of financing costs(6,898)(875)
Earn-out payments for prior acquisitions(10,622)(5,700)
Cash paid for shares withheld for taxes(4,798)(13,342)
Net cash provided by financing activities266,557 136,440 
Effect of exchange rate changes on cash(119)(58)
Net increase (decrease) in cash, cash equivalents and restricted cash(45,039)28,981 
Cash, cash equivalents and restricted cash at beginning of period153,962 84,324 
Cash, cash equivalents and restricted cash at end of period$108,923 $113,305 
Supplemental disclosures of cash flow information:
Cash paid for amounts included in the measurement of operating lease liabilities$15,079 $13,294 
Cash paid for interest (net of $300 and $363 capitalized for the nine months ended September 30, 2020 and 2019, respectively)$13,848 $14,988 
Cash paid for income taxes$30,727 $32,457 
Acquisitions:
Fair value of tangible assets acquired in acquisitions, net of cash and restricted cash received$35,704 $28,542 
Goodwill274,427 148,095 
Intangible assets228,000 98,580 
Liabilities assumed(61,640)(34,873)
Earn-out liabilities(12,122)
Net cash paid for acquisitions$476,491 $228,222 
Supplemental disclosures of non-cash investing and financing activities:
Purchase of fixed assets recorded in accounts payable and accrued expenses$1,007 $2,142 
 Nine Months Ended September 30,
 2019 2018
Cash flows from financing activities:   
Payments on term loans(938) 
Proceeds from term loans150,000
 
Payments on revolving credit facility(75,000) (45,000)
Proceeds from revolving credit facility101,000
 195,000
Repurchase of common stock(18,705) (52,750)
Payment of financing costs(875) (2,331)
Earn-out payments for prior acquisitions(5,700) (1,713)
Cash paid for shares withheld for taxes(13,342) (11,432)
Net cash provided by financing activities136,440
 81,774
Effect of exchange rate changes on cash(58) 205
Net increase (decrease) in cash, cash equivalents and restricted cash28,981
 (21,623)
Cash, cash equivalents and restricted cash at beginning of period84,324
 98,894
Cash, cash equivalents and restricted cash at end of period$113,305
 $77,271
    
Supplemental disclosures of cash flow information:   
Cash paid for amounts included in the measurement of operating lease liabilities$13,294
 $
Cash paid for interest (net of $363 and $368 capitalized for the nine months ended September 30, 2019 and 2018, respectively)$14,988
 $11,521
Cash paid for income taxes$32,457
 $21,223
Acquisitions:   
Fair value of tangible assets acquired in acquisitions, net of cash and restricted cash received$28,542
 $24,027
Goodwill148,095
 97,703
Intangible assets98,580
 122,111
Liabilities assumed(34,873) (16,380)
Earn-out liabilities(12,122) (10,100)
Net cash paid for acquisitions$228,222
 $217,361
Supplemental disclosures of non-cash investing and financing activities:   
Purchase of fixed assets recorded in accounts payable and accrued expenses$2,142
 $4,504

See accompanying notes to unaudited condensed consolidated financial statements.
6


AMN HEALTHCARE SERVICES, INC.
 
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share amounts)
 
1. BASIS OF PRESENTATION
The condensed consolidated balance sheets and related condensed consolidated statements of comprehensive income and cash flows contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”), which are unaudited, include the accounts of AMN Healthcare Services, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The results of operations for the interim period are not necessarily indicative of the results to be expected for any other interim period or for the entire fiscal year or for any future period.
The unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Please refer to the Company’s audited consolidated financial statements and the related notes for the fiscal year ended December 31, 2018,2019, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018,2019, filed with the Securities and Exchange Commission on February 21, 25, 2020 (“2019 (“2018 Annual Report”).
The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. Actual results could differ from those estimates under different assumptions or conditions.
Coronavirus Pandemic
On March 11, 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, also known as COVID-19, a global pandemic. Due to the pandemic, there has been uncertainty and disruption in the global economy and significant volatility of financial markets. The Company is closely monitoring the impact of the pandemic, which continues to evolve, and its effects and risks on our operations, liquidity, financial condition and financial results for the full year 2020 and, possibly, beyond. The Company also implemented remote-work arrangements effective mid-March 2020 and, to date, transitioning to a remote-work environment has not had a material adverse impact on the Company’s ability to continue to operate its business, financial reporting process or internal controls and procedures.
The estimates used for, but not limited to, determining the collectability of accounts receivable, fair value of long-lived assets, and goodwill could be impacted by the pandemic. While the full impact of COVID-19, including the duration and severity of the pandemic, remains unknown, the Company has made appropriate estimates based on the facts and circumstances available as of the reporting date. Specifically, the Company continues to monitor the impacts of the pandemic on its customers’ liquidity and capital resources and, therefore, the Company’s ability to collect, or the timeliness of collection of accounts receivable. The impact of COVID-19 did not have a material effect on the Company’s estimates as of September 30, 2020. These estimates may change as new events occur and additional information is obtained. See additional information below regarding the allowance for credit losses for accounts receivable.
Recently Adopted Accounting Pronouncements
In FebruaryJune 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-02, “Leases.2016-13, “Measurement of Credit Losses on Financial Instruments.The FASB also issued a series of other ASUs, which update ASU 2016-13 (collectively, the “credit loss standard”). This new standard requires organizations that lease assets to recognizeintroduces new accounting models for determining and recognizing credit losses on certain financial instruments based on an estimate of current expected credit losses. The Company adopted this standard effective January 1, 2020 using the assets and liabilities created by those leases. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required, applying the standard to all leases existing at the date of initial application. In addition, the FASB has also issued several amendments to the standard, which clarify certain aspects of the guidance, including an optional transition method for adoption of this standard, which allows organizations to initially apply the new requirements at the effective date, recognize a cumulative effect adjustment to the opening balance of retained earnings, and continue to apply the legacy guidance in Accounting Standards Codification (“ASC”) 840, Leases, including its disclosure requirements, in the comparative periods presented. The new standard provides a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits organizations not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect to use the hindsight practical expedient to determine the lease term or evaluate impairment for existing leases.
The Company adopted ASU 2016-02 effective January 1, 2019, using the optional transition method described above.method. The Company recognized the cumulative effect of adopting this guidance as an adjustment asto the opening balance of the effective date,retained earnings of $1,154, net of tax, primarily related to the recognition of lease liabilities of $114,807 and corresponding right-of-use assets of $99,525its allowance for existing operating leases. The Company also derecognized existing deferred rent liabilities of $15,302. These adjustments had no effect on opening retained earnings and prior periods werecredit losses for accounts receivable. Prior period amounts are not retrospectively adjusted and continue to be reported in accordance with ASC 840.adjusted. The new standard also provides practical expedients for an organization’s ongoing accounting. The Company elected the short-term lease recognition exemption and the practical expedient to not separate lease and non-lease components for all leases that qualify. The Company does not expectimpact of the adoption of thisthe new standard to impact its results of operations.

There was no othernot material impact to the Company’s condensed consolidated financial statements asfor the three and nine months ended September 30, 2020. The Company expects the impact to
7


be immaterial on an ongoing basis. See additional information below regarding the allowance for credit losses for accounts receivable.
In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a resulthypothetical purchase price allocation to compute the implied fair value of adoptinggoodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. The Company adopted this updated standard.standard effective January 1, 2020 and the adoption did not have a material effect on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The standard modifies the current disclosure requirements on fair value measurements. The Company adopted this standard effective January 1, 2020. Refer to information regarding fair value measurements in Note (7), “Fair Value Measurement.”
Cash, cash equivalentsCash Equivalents and restricted cashRestricted Cash
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents include currency on hand, deposits with financial institutions and highly liquid investments. Restricted cash and cash equivalents primarily represent cash and money market funds on deposit with financial institutions and investments represents commercial paper that serves as collateral for the Company’s outstanding letters of credit and captive insurance subsidiary claim payments. See Note (6), “Notes Payable and Credit Agreement” and Note (7), “Fair Value Measurement” for additional information.
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets and related notes to the amounts presented in the accompanying condensed consolidated statements of cash flows.
 September 30, 2020December 31, 2019
Cash and cash equivalents$58,419 $82,985 
Restricted cash and cash equivalents (included in other current assets)15,194 18,393 
Restricted cash, cash equivalents and investments60,898 62,170 
Total cash, cash equivalents and restricted cash and investments134,511 163,548 
Less restricted investments(25,588)(9,586)
Total cash, cash equivalents and restricted cash$108,923 $153,962 
 September 30, 2019 December 31, 2018
Cash and cash equivalents$40,748
 $13,856
Restricted cash and cash equivalents (included in other current assets)16,885
 26,329
Restricted cash, cash equivalents and investments59,165
 59,331
Total cash, cash equivalents and restricted cash and investments116,798
 99,516
Less restricted investments(3,493) (15,192)
Total cash, cash equivalents and restricted cash$113,305
 $84,324
Accounts Receivable


The Company records accounts receivable at the invoiced amount. Accounts receivable are non-interest bearing. The Company maintains an allowance for expected credit losses based on the Company’s historical write-off experience, an assessment of its customers’ financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions.
The following table provides a reconciliation of activity in the allowance for credit losses for accounts receivable:
2020
Balance as of January 1,$3,332 
Adoption of the credit loss standard, cumulative-effect adjustment to retained earnings1,334 
Provision for expected credit losses5,178 
Amounts written off charged against the allowance(1,333)
Balance as of September 30,$8,511 
Reclassification
The Company reclassified its allowance for accounts receivable in the prior year’s consolidated balance sheet to conform to the current year presentation. The prior year’s balance of accounts receivable (net of allowances) remains unchanged.

8


2. ACQUISITIONS
As set forth below, the Company completed 4 acquisitions from January 1, 20182019 through September 30, 2019.2020. The Company accounted for each acquisition using the acquisition method of accounting. Accordingly, it recorded the tangible and intangible assets acquired and liabilities assumed at their estimated fair values as of the applicable date of acquisition. Since the applicable date of acquisition, the Company has revised the allocation of the purchase price to the tangible and intangible assets acquired and liabilities assumed based on analysis of information that has been made available through September 30, 2019.2020. The allocations noted as preliminary will continue to be updated through the measurement period, if necessary. ForThe Company recognizes acquisition-related costs in selling, general and administrative expenses in the consolidated statements of comprehensive income.
Stratus Video Acquisition
On February 14, 2020, the Company completed its acquisition of Stratus Video, a remote video interpreting company that provides healthcare interpretation via remote video, over the phone, and onsite in-person, all supported by proprietary technology platforms. The initial purchase price of $485,568 consisted entirely of cash consideration paid upon acquisition. The acquisition was funded primarily through (1) borrowings under the Company’s $400,000 secured revolving credit facility (the “Senior Credit Facility”), provided for under a credit agreement (the “New Credit Agreement”), and (2) the Second Amendment (as defined in Note (6) below) to the New Credit Agreement, which provided $250,000 of additional available borrowings to the Company. The New Credit Agreement and the Second Amendment are more fully described in Note (6), “Notes Payable and Credit Agreement.” The results of Stratus Video have been included in the Company’s technology and workforce solutions segment since the date of acquisition. During the second quarter of 2020, an additional $99 of cash consideration was paid to the selling shareholders for the final working capital settlement. The Company incurred $10,548 of acquisition-related costs during the nine months ended September 30, 2020 as a result of its acquisition of Stratus Video.
The preliminary allocation of the $485,667 purchase price, which included the additional cash consideration paid for the final working capital settlement, consisted of (1) $44,880of fair value of tangible assets acquired, which included $9,176 cash received, (2) $61,640 of liabilities assumed, (3) $228,000 of identified intangible assets, and (4) $274,427 of goodwill, of which $10,186 is expected to be deductible for tax purposes. The provisional items pending finalization are the valuation of the acquired intangible assets and income tax related matters. The intangible assets acquired have a weighted average useful life of approximately seventeen years. The following table summarizes the fair value and useful life of each intangible asset acquired as of the acquisition date:
Fair ValueUseful Life
(in years)
Identifiable intangible assets
Customer Relationships$171,000 20
Tradenames and Trademarks40,000 5 - 10
Developed Technology16,000 5
Interpreter Database1,000 4
$228,000 
During the third quarter of 2020, the Company revised the estimated useful lives for the tradenames and trademarks intangible assets as a result of its plan to rebrand the language interpretation business. Based on this change in circumstances since the date of acquisition, the Company diddetermined that the remaining useful lives of the assets are 5 years and will amortize the remaining value on a straight-line basis over the remaining useful life. The Company will continue to evaluate the remaining useful lives of other intangible assets impacted by its brand consolidation efforts.
Approximately $35,329 of revenue and $8,322 of income before income taxes of Stratus Video were included in the unaudited condensed consolidated statement of comprehensive income for the three months ended September 30, 2020. Approximately $78,080 of revenue and $13,787 of income before income taxes of Stratus Video were included in the unaudited condensed consolidated statement of comprehensive income for the nine months ended September 30, 2020. The following summary presents unaudited pro forma consolidated results of operations of the Company as if the Stratus Video and Advanced (as defined below) acquisitions had occurred on January 1, 2019, which gives effect to certain adjustments, including incremental acquisition-related costs of $4,512 and $20,438, of which $1,023 and $11,662 were reclassified from the three and nine months ended September 30, 2020, respectively, amortization of intangible assets of $1,307 and $10,924, and interest expense of $1,246 and $5,465 during the three and nine months ended September 30, 2019, respectively. The pro forma
9


financial information is not incur any material acquisition-related costs.necessarily indicative of the operating results that would have occurred had the acquisitions been consummated as of the date indicated, nor is it necessarily indicative of the Company’s future operating results.
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Revenue$551,631 $595,211 $1,776,315 $1,767,010 
Income from operations50,465 36,202 135,618 101,718 
Net income29,030 17,850 71,434 54,667 
b4health Acquisition
On December 19, 2019, the Company completed its acquisition of B4Health, LLC (“b4health”), an innovative technology company and a leading provider of a web-based internal float pool management solution and vendor management system for healthcare facilities. The initial purchase price of $23,006 included (1) $19,906 cash consideration paid upon acquisition and (2) a contingent earn-out payment of up to $12,000 with an estimated fair value of $3,100 as of the acquisition date. The contingent earn-out payment is based on the operating results of b4health for the twelve months ending December 31, 2020. The results of b4health have been included in the Company’s technology and workforce solutions segment since the date of acquisition. During the first quarter of 2020, $66 was returned to the Company for the final working capital settlement.
The allocation of the $22,940 purchase price, which was reduced by the final working capital settlement, consisted of (1) $1,169 of fair value of tangible assets acquired, which included $222 cash received, (2) $823 of liabilities assumed, (3) $9,000 of identified intangible assets, and (4) $13,594 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $3,000 of developed technology, $4,000 of customer relationships, and $2,000 of trademarks with a weighted average useful life of approximately seven years.
Advanced Acquisition
On June 14, 2019, the Company completed its acquisition of Advanced Medical Personnel Services, Inc. (“Advanced”), a national healthcare staffing company that specializes in placing therapists and nurses across multiple settings. The initial purchase price of $211,743 included (1) $201,121 cash consideration paid upon acquisition and (2) a contingent earn-out payment of up to $20,000 with an estimated fair value of $10,622 as of the acquisition date. The contingent earn-out payment is based on the operating results of Advanced for the twelve months ending December 31, 2019.2019, which was settled in full during the first quarter of 2020. The acquisition was funded primarily through (1) borrowings under the Company’s $400,000 secured revolving credit facility (the “SeniorSenior Credit Facility”), provided for under a credit agreement (the “New Credit Agreement”), dated as of February 9, 2018,Facility and (2) the First Amendment (as defined in Note (6) below) to the New Credit Agreement, which provided $150,000 of additional available borrowings to the Company. The New Credit Agreement and the First Amendment are more fully described in Note (6), “Notes Payable and Credit Agreement.” The results of Advanced have been included in the Company’s nurse and allied solutions segment since the date of acquisition. During the third quarter of 2019, an additional $73 of cash consideration was paid to the selling shareholders for the final working capital settlement.
The preliminary allocation of the $211,816 purchase price, which included the additional cash consideration paid for the final working capital settlement, consisted of (1) $30,013$29,020 of fair value of tangible assets acquired, which included $2,497 cash and restricted cash received, (2) $31,483$28,772 of liabilities assumed, (3) $91,700 of identified intangible assets, and (4) $121,586$119,868 of goodwill, of which $56,936$57,236 is expected to be deductible for tax purposes. The provisional items pending finalization are the valuation of the acquired intangible assets, goodwill, and income tax related matters. The intangible assets acquired have a weighted average useful life of approximately nine years. The following table summarizes the fair value and useful life of each intangible asset acquired:
Fair ValueUseful Life
(in years)
Identifiable intangible assets
Customer Relationships$68,000 10
Tradenames and Trademarks10,000 5
Staffing Database10,300 10
Developed Technology3,400 3
$91,700 



10

   Fair Value Useful Life
     (in years)
Identifiable intangible assets    
 Customer Relationships $68,000
 10
 Tradenames and Trademarks 10,000
 5
 Staffing Database 10,300
 10
 Developed Technology 3,400
 3
   $91,700
  

Silversheet Acquisition
On January 30, 2019, the Company completed its acquisition of Silversheet, Inc. (“Silversheet”), which provides innovative software and services to reduce the complexities and challenges of the credentialing process for clinicians and healthcare organizations. The initial purchase price of $31,676 included (1) $30,176 cash consideration paid upon acquisition, funded primarily through borrowings under the Senior Credit Facility, and (2) a contingent earn-out payment of up to $25,000 with an estimated fair value of $1,500 as of the acquisition date. The contingent earn-out payment is based on (A) up to $6,000 based on the operating results of Silversheet for the twelve months ending December 31, 2019, which resulted in no earn-out payment, and (B) up to $19,000 based on the operating results of Silversheet for the twelve months ending December 31, 2020. The results of Silversheet have been included in the Company’s othertechnology and workforce solutions segment since the date of acquisition.
The preliminary allocation of the $31,676 purchase price consisted of (1) $1,677$2,826 of fair value of tangible assets acquired, which included $651 cash received, (2) $3,390$1,567 of liabilities assumed, (3) $6,880 of identified intangible assets, and (4) $26,509$23,537 of goodwill, none of which is deductible for tax purposes. The provisional items pending finalization are the valuation of the acquired intangible assets, goodwill, and income tax related matters. The fair value of intangible assets primarily includes $5,300 of developed technology and $1,500 of trademarks with a weighted average useful life of approximately eight years.

MedPartners Acquisition
On April 9, 2018, the Company completed its acquisition of MedPartners HIM (“MedPartners”), which provides case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. The initial purchase price of $200,933 included (1) $196,533 cash consideration paid upon acquisition, funded primarily through borrowings under the Senior Credit Facility, and (2) a contingent earn-out payment of up to $20,000 with an estimated fair value of $4,400 as of the acquisition date. The contingent earn-out payment is based on (A) up to $10,000 based on the operating results of MedPartners for the twelve months ending December 31, 2018, which resulted in no earn-out payment, and (B) up to $10,000 based on the operating results of MedPartners for the six months ending June 30, 2019. The results of MedPartners have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $222 was returned to the Company for the final working capital settlement.
The allocation of the $200,711 purchase price, which was reduced by the final working capital settlement and finalized during the second quarter of 2019, consisted of (1) $28,508 of fair value of tangible assets acquired, which included $8,403 cash received, (2) $11,933 of liabilities assumed, (3) $103,000 of identified intangible assets, and (4) $81,136 of goodwill, all of which is deductible for tax purposes. The intangible assets acquired have a weighted average useful life of approximately sixteen years. The following table summarizes the fair value and useful life of each intangible asset acquired as of the acquisition date:
   Fair Value Useful Life
     (in years)
Identifiable intangible assets    
 Tradenames and Trademarks $46,000
 20
 Customer Relationships 57,000
 12
   $103,000
  

During the third quarter of 2019, the Company shortened the estimated useful life for the tradenames and trademarks intangible asset as a result of its plan to rebrand the revenue cycle solutions business. Based on this change in circumstances since the date of acquisition, the Company determined that the remaining useful life of this asset was five years and began amortizing its remaining value on a straight-line basis over the remaining useful life.
Phillips DiPisa and Leaders For Today Acquisition
On April 6, 2018, the Company completed its acquisition of 2 related entities, Phillips DiPisa and Leaders For Today (“PDA and LFT”), which offer a range of leadership staffing and permanent placement solutions for the healthcare industry. The initial purchase price of $35,968 included (1) $30,268 cash consideration paid upon acquisition, funded through cash on hand, and (2) a contingent earn-out payment of up to $7,000 with an estimated fair value of $5,700 as of the acquisition date. The contingent earn-out payment is based on the operating results of PDA and LFT for the twelve months ending December 31, 2018, which was settled in full during the second quarter of 2019. The results of PDA and LFT have been included in the Company’s other workforce solutions segment since the date of acquisition. During the third quarter of 2018, $465 was returned to the Company for the final working capital settlement.
The allocation of the $35,503 purchase price, which was reduced by the final working capital settlement and finalized during the second quarter of 2019, consisted of (1) $4,389 of fair value of tangible assets acquired, which included $351 cash received, (2) $4,779 of liabilities assumed, (3) $19,110 of identified intangible assets, and (4) $16,783 of goodwill, all of which is deductible for tax purposes. The fair value of intangible assets includes $5,400 of trademarks, $8,000 of customer relationships and $5,710 of staffing databases with a weighted average useful life of approximately twelve years.

3. REVENUE RECOGNITION
Revenue primarily consists of fees earned from the temporary staffing and permanent placement of healthcare professionals, executives, and executivesleaders (clinical and operational). The Company also generates revenue from its software as well as from the Company’s SaaS-based technology,a service (“SaaS”)-based technologies, including its vendor management systems and its scheduling software. Revenue is recognizedsoftware, and outsourced workforce services, including language interpretation and recruitment process outsourcing. The Company recognizes revenue when control of theseits services is transferred to theits customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. Revenue from temporary staffing services is recognized as the services are rendered by clinical and non-clinical healthcare professionals. Under the Company’s managed services program (“MSP”) arrangements, the Company manages all or a part of a customer’s supplemental workforce needs utilizing its own network of healthcare professionals along with those of third-party subcontractors. Revenue and the related direct costs under MSP arrangements are recorded in accordance with the accounting guidance on reporting revenue gross as a principal versus net as an agent. When the Company uses subcontractors and acts as an agent, revenue is recorded net of the related

subcontractor’s expense. Revenue from executive search, physician permanent placement and recruitment process outsourcingoutsourced workforce services is recognized as the services are rendered. TheDepending on the arrangement, the Company’s SaaS-based revenue is recognized either as the services are rendered or ratably over the applicable arrangement’s service period.
The Company’s customers are primarily billed as services are rendered. Any fees billed in advance of being earned are recorded as deferred revenue. While payment terms vary by the type of customer and the services rendered, the term between invoicing and when payment is due is not significant. During the nine months ended September 30, 2020 and 2019, previously deferred revenue recognized as revenue was $9,498.$11,408 and $9,498, respectively.
The Company has elected to apply the following practical expedients and optional exemptions related to contract costs and revenue recognition:
Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within selling, general and administrative expenses.
Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date.
Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation.
See Note (5), “Segment Information” for additional information.

11


4. NET INCOME PER COMMON SHARE
Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period. The following table sets forth the computation of basic and diluted net income per common share:
 Three Months Ended September 30, Nine Months Ended September 30,
 2019 2018 2019 2018
Net income$23,515
 $27,918
 $86,506
 $106,128
        
Net income per common share - basic$0.50
 $0.59
 $1.85
 $2.23
Net income per common share - diluted$0.49
 $0.58
 $1.82
 $2.17
        
Weighted average common shares outstanding - basic46,677
 47,286
 46,701
 47,556
Plus dilutive effect of potential common shares930
 1,243
 899
 1,303
Weighted average common shares outstanding - diluted47,607
 48,529
 47,600
 48,859

 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Net income$26,067 $23,515 $61,357 $86,506 
Net income per common share - basic$0.55 $0.50 $1.29 $1.85 
Net income per common share - diluted$0.55 $0.49 $1.29 $1.82 
Weighted average common shares outstanding - basic47,476 46,677 47,406 46,701 
Plus dilutive effect of potential common shares200 930 241 899 
Weighted average common shares outstanding - diluted47,676 47,607 47,647 47,600 
Share-based awards to purchase 84 and 79 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2020, respectively, because the effect of these instruments was anti-dilutive. Share-based awards to purchase 32 and 55 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2019, respectively, because the effect of these instruments was anti-dilutive. Share-based awards to purchase 36 and 27 shares of common stock were not included in the above calculation of diluted net income per common share for the three and nine months ended September 30, 2018, respectively, because the effect of these instruments was anti-dilutive.

5. SEGMENT INFORMATION
The Company’s operating segments are identified in the same manner as they are reported internally and used by the Company’s chief operating decision maker for the purpose of evaluating performance and allocating resources. Effective March 8, 2020, the Company hasmodified its reportable segments. The Company previously utilized 3 reportable segments:segments, which it identified as follows: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. In light of the Company’s recent acquisitions and organizational changes to better align its organizational structure with its strategy and operations, the Company’s management reorganized its reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2020, the Company has disclosed the following 3 reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The nurse and allied solutions segment includes the Company’s travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The physician and leadership solutions segment includes the Company’s locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes the Company’s language interpretation services, vendor management systems, workforce optimization, recruitment process outsourcing, credentialing, and flex pool management businesses.
The Company’s chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income represents income before income taxes plus depreciation, amortization of intangible assets, share-based compensation, interest expense, net, and other, and unallocated corporate overhead. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table, which includes reclassified prior period data to conform to the new segment reporting structure, provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes:

 Three Months Ended September 30, Nine Months Ended September 30,
 2019
2018 2019 2018
Revenue       
Nurse and allied solutions$362,533
 $306,292
 $1,031,189
 $977,199
Locum tenens solutions84,164
 101,102
 246,728
 311,516
Other workforce solutions120,900
 119,448
 357,298
 318,724
 $567,597
 $526,842
 $1,635,215
 $1,607,439
Segment operating income       
Nurse and allied solutions$47,544
 $42,165
 $144,160
 $137,906
Locum tenens solutions6,156
 10,992
 18,985
 34,321
Other workforce solutions27,806
 29,010
 81,121
 77,437
 81,506
 82,167
 244,266
 249,664
Unallocated corporate overhead21,857
 26,427
 61,093
 59,271
Depreciation and amortization17,085
 11,296
 41,513
 29,788
Share-based compensation2,825
 1,809
 11,713
 7,954
Interest expense, net, and other7,830
 4,649
 19,568
 16,360
Income before income taxes$31,909
 $37,986
 $110,379
 $136,291
12


 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Revenue
Nurse and allied solutions$382,699 $398,417 $1,251,509 $1,139,883 
Physician and leadership solutions109,116 143,842 355,580 423,368 
Technology and workforce solutions59,816 25,338 155,354 71,964 
$551,631 $567,597 $1,762,443 $1,635,215 
Segment operating income
Nurse and allied solutions$52,923 $52,533 $173,706 $158,841 
Physician and leadership solutions15,538 17,547 45,432 52,280 
Technology and workforce solutions25,680 11,426 62,814 33,145 
94,141 81,506 281,952 244,266 
Unallocated corporate overhead16,490 21,857 76,223 61,093 
Depreciation and amortization26,936 17,085 69,096 41,513 
Depreciation (included in cost of revenue)481 981 
Share-based compensation3,772 2,825 15,046 11,713 
Interest expense, net, and other12,564 7,830 35,061 19,568 
Income before income taxes$33,898 $31,909 $85,545 $110,379 
13


The following tables present the Company’s revenue disaggregated by service type. Certain prior period amounts have been reclassified to conform with current period presentation. These reclassifications have no impact on total revenue by reportable segment.
Three Months Ended September 30, 2020
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$382,699 $95,648 $$478,347 
Permanent placement13,468 13,468 
Outsourced workforce38,159 38,159 
SaaS-based technologies21,657 21,657 
Total revenue$382,699 $109,116 $59,816 $551,631 
Three Months Ended September 30, 2019
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$398,417 $123,540 $$521,957 
Permanent placement20,302 20,302 
Outsourced workforce4,643 4,643 
SaaS-based technologies20,695 20,695 
Total revenue$398,417 $143,842 $25,338 $567,597 
Nine Months Ended September 30, 2020
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$1,251,509 $310,945 $$1,562,454 
Permanent placement44,635 44,635 
Outsourced workforce87,705 87,705 
SaaS-based technologies67,649 67,649 
Total revenue$1,251,509 $355,580 $155,354 $1,762,443 
Nine Months Ended September 30, 2019
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Temporary staffing$1,139,883 $364,551 $$1,504,434 
Permanent placement58,817 58,817 
Outsourced workforce12,435 12,435 
SaaS-based technologies59,529 59,529 
Total revenue$1,139,883 $423,368 $71,964 $1,635,215 
In connection with the reorganization of its reportable segments effective March 8, 2020, the Company reassigned the goodwill balances to the reporting units, the composition of which changed under the reorganized reportable segments, using the relative fair value reallocation approach. The Company offersperformed a comprehensive managed services program, in whichgoodwill impairment test at the reporting unit level both immediately before and after the reorganization. The Company determined the fair values of its reporting units using a combination of the income approach (using discounted future cash flows) and the market valuation approach. Based on the results of this testing, the Company manages all or a portiondetermined that the fair values of a client’s contingent staffing needs. This service includesits reporting units were each greater than their respective carrying values both before and after the placement of the Company’s own healthcare professionals and the utilization of other staffing agencies to fulfill the client’s staffing needs. See additional information in Note (3), “Revenue Recognition.” For the three months ended September 30, 2019 and 2018, revenue under the Company’s managed services program arrangements comprised approximately 60% and 61% for nurse and allied solutions revenue, 23% and 17% for locum tenens solutions revenue and 9% and 5% for other workforce solutions revenue, respectively. Forreorganization. Therefore, there was 0 impairment loss recognized during the nine months ended September 30, 2019 and 2018, revenue under the Company’s managed services program arrangements comprised approximately 64% and 60% for nurse and allied solutions revenue, 23% and 16% for locum tenens solutions revenue and 9% and 7% for other workforce solutions revenue, respectively.2020.
14


The following table summarizes the activity related to the carrying value of goodwill by reportable segment:
Nurse and Allied SolutionsPhysician and Leadership SolutionsTechnology and Workforce SolutionsTotal
Balance, January 1, 2020$344,316 $163,348 $87,887 $595,551 
Goodwill adjustment for Advanced acquisition29 29 
Goodwill adjustment for b4health acquisition(66)(66)
Goodwill from Stratus Video acquisition274,427 274,427 
Reallocation due to change in segments(14,600)297 14,303 
Balance, September 30, 2020$329,745 $163,645 $376,551 $869,941 
Accumulated impairment loss as of December 31, 2019 and September 30, 2020$154,444 $60,495 $$214,939 
 Nurse and Allied Solutions Locum Tenens Solutions Other Workforce Solutions Total
Balance, January 1, 2019$103,107
 $19,743
 $315,656
 $438,506
Goodwill adjustment for MedPartners acquisition
 
 23
 23
Goodwill adjustment for PDA and LFT acquisition
 
 (13) (13)
Goodwill from Silversheet acquisition
 
 26,509
 26,509
Goodwill from Advanced acquisition121,586
 
 
 121,586
Balance, September 30, 2019$224,693
 $19,743
 $342,175
 $586,611
Accumulated impairment loss as of December 31, 2018 and September 30, 2019$154,444
 $53,940
 $6,555
 $214,939


6. NOTES PAYABLE AND CREDIT AGREEMENT

The Company’s Credit Agreement and Related Credit Facilities
On February 9, 2018, the Company entered into the New Credit Agreement with several lenders to provide for the $400,000 Senior Credit Facility to replace its then-existing credit facilities. The Senior Credit Facility includes a $50,000 sublimit for the issuance of letters of credit and a $50,000 sublimit for swingline loans. On June 14, 2019, the Company entered into the first amendment to the New Credit Agreement (the “First Amendment”) to provide for, among other things, a $150,000 secured term loan credit facility (the “Term Loan”). The First Amendment (together with the New Credit Agreement, the “Amended Credit Agreement”) also extended the maturity date of the Senior Credit Facility to be coterminous with the Term Loan. The obligations of the Company under the Amended Credit Agreement are secured by substantially all of the assets of the Company. The Company used the proceeds from the Term Loan, together with a drawdown of a portion of the Senior Credit Facility, to complete its acquisition of Advanced, as more fully described in Note (2), “Acquisitions.” The Company fully repaid all amounts under the Term Loan in 2019.


On February 14, 2020, the Company entered into the second amendment to the New Credit Agreement (the “Second Amendment”) to provide for, among other things, a $250,000 secured term loan credit facility (the “Additional Term Loan”). The Second Amendment (together with the New Credit Agreement and the First Amendment, collectively, the “Amended Credit Agreement”) extended the maturity date of the Senior Credit Facility to be coterminous with the Additional Term Loan. The obligations of the Company under the Amended Credit Agreement are secured by substantially all of the assets of the Company. The Company used the proceeds from the Additional Term Loan, together with a drawdown of a portion of the Senior Credit Facility, to complete its acquisition of Stratus Video as more fully described in Note (2), “Acquisitions.”

Borrowings under the Senior Credit Facility and the Additional Term Loan (together, the “Credit Facilities”) bear interest at floating rates, at the Company’s option, based upon either LIBOR plus a spread of 1.00% to 2.00%1.75% or a base rate plus a spread of 0.00% to 1.00%0.75%. The applicable spread is determined quarterly based upon the Company’s consolidated net leverage ratio.ratio (as calculated per the Amended Credit Agreement). The Additional Term Loan is subject to amortization of principal of 2.50% per year for the first year of the term and 5.00% per year thereafter, payable in equal quarterly installments. The Senior Credit Facility is available for working capital, capital expenditures, permitted acquisitions and general corporate purposes. The maturity date of the Credit Facilities is JuneFebruary 14, 2024.2025.

In connection with the FirstSecond Amendment, the Company incurred $875$3,899 in fees paid to lenders and other third parties, which were capitalized during the three months ended June 30, 2019March 31, 2020 and are amortized to interest expense over the term of the Credit Facilities. In addition, $1,702$1,681 of unamortized financing fees incurred in connection with obtaining the New Credit Agreement and First Amendment will continue to be amortized to interest expense over the term of the Credit Facilities.

4.625% Senior Notes Due 2027
In connection withOn August 13, 2020, the Company'sCompany completed the issuance of an additional $200,000 aggregate principal amount of the 4.625% senior notes due 2027 (the “New 2027 Notes”), which were issued at a price of 101.000% of the aggregate principal amount. The New 2027 Notes were issued pursuant to the existing indenture, dated as of October 1, 2019, under which the Company previously issued $300,000 aggregate principal amount of 4.625% Senior Notessenior notes due 2027 (the “Existing 2027 Notes” and together with the New 2027 Notes, the “2027 Notes”). The New 2027 Notes will be treated as a single series with the Existing 2027 Notes and will have the same terms (other than issue price, issue date and the date from which interest accrues) as those of the Existing 2027 Notes. Interest on the 2027 Notes is payable semi-annually in arrears on April 1 and October 1 of each year, commencing October 1, 2020 with respect to the New 2027 Notes. The terms of the Existing 2027 Notes, including maturity date and interest terms, are disclosed in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note 8—Notes Payable and Credit Agreement” of the 2019 Annual Report.
15


With proceeds from the New 2027 Notes, the Company used a portion of the proceeds to repay $295,063(1) repaid $200,000 of its indebtedness under the existing Additional Term Loan and (2) paid $2,717 of fees and expenses related to the issuance of the New 2027 Notes, which were recorded as a reduction of the notes payable balance and are being amortized to interest expense over the remaining term of the 2027 Notes.
4.000% Senior Notes Due 2029
On October 20, 2020, the Company completed the issuance of $350,000 aggregate principal amount of 4.000% senior notes due 2029 (the “2029 Notes”). The Company used the proceeds (1) to redeem all of its outstanding $325,000 aggregate principal amount of 5.125% senior notes due 2024 (the “2024 Notes”) and (2) to repay a portion of its indebtedness under the Senior Credit Facilities.Facility. See additional information in Note (12)(11), “Subsequent Events.”

7. FAIR VALUE MEASUREMENT
 
The Company’s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note 3—Fair Value Measurement” of the 20182019 Annual Report. The Company has not changed the valuation techniques or inputs it uses for its fair value measurement during the three and nine months ended September 30, 2019.2020.
Assets and Liabilities Measured on a Recurring Basis
The Company’s restricted cash equivalents that serve as collateral for the Company’s outstanding letters of credit
typically consist of money market funds that are measured at fair value based on quoted prices, which are Level 1 inputs.

The Company has a deferred compensation plan for certain executives and key employees, which is composed of deferred compensation and all related income and losses attributable thereto. The Company’s obligation under its deferred compensation plan is measured at fair value based on quoted market prices of the participants’ elected investments, which are Level 1 inputs.
The Company’s restricted cash equivalents and investments that serve as collateral for the Company’s captive insurance company primarily consist of commercial paper that is measured at observable market prices for identical securities that are traded in less active markets, which are Level 2 inputs. Of the $59,244$59,196 commercial paper issued and outstanding as of September 30, 2019, $3,4932020, $25,588 had original maturities greater than three months, which were considered available-for-sale securities. As of December 31, 2018,2019, the Company had $63,243$59,243 commercial paper issued and outstanding, of which $15,192$9,586 had original maturities greater than three months and were considered available-for-sale securities.
The Company’s contingent consideration liabilities are measured at fair value using a probability-weighted discounted cash flow analysis or a simulation-based methodology for the acquired companies, which are Level 3 inputs. The Company recognizes changes to the fair value of its contingent consideration liabilities in selling, general and administrative expenses in the condensed consolidated statements of comprehensive income.
The following tables present information about the above-referenced assets and liabilities and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value:
 Fair Value Measurements as of September 30, 2019
 Total 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Money market funds$2,498
 $2,498
 $
 $
Commercial paper59,244
 
 59,244
 
Acquisition contingent consideration liabilities(15,105) 
 
 (15,105)
 Fair Value Measurements as of September 30, 2020
 TotalQuoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Money market funds$2,354 $2,354 $$
Deferred compensation(87,934)(87,934)
Commercial paper59,196 59,196 
Acquisition contingent consideration liabilities(1,400)(1,400)


 Fair Value Measurements as of December 31, 2018
 Total 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Money market funds$2,461
 $2,461
 $
 $
Commercial paper63,243
 
 63,243
 
Acquisition contingent consideration liabilities(7,700) 
 
 (7,700)
16



 Fair Value Measurements as of December 31, 2019
 TotalQuoted Prices in
Active Markets
for Identical
Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Money market funds$2,508 $2,508 $$
Deferred compensation(81,064)(81,064)
Commercial paper59,243 59,243 
Acquisition contingent consideration liabilities(23,100)(23,100)
17


Level 3 Information
The following tables settable sets forth a reconciliation of changes in the fair value of contingent consideration liabilities classified as Level 3 in the fair value hierarchy:
 Three Months Ended September 30,
 2019 2018
Balance as of July 1,$(10,664)
$(10,119)
Change in fair value of contingent consideration liability from PDA and LFT acquisition
 (1,194)
Change in fair value of contingent consideration liability from MedPartners acquisition
 2,520
Change in fair value of contingent consideration liability from Silversheet acquisition42
 
Change in fair value of contingent consideration liability from Advanced acquisition(4,483) 
Balance as of September 30,$(15,105) $(8,793)
 Nine Months Ended September 30,
 2019 2018
Balance as of January 1,$(7,700) $(2,070)
Settlement of HSG contingent consideration liability for year ended December 31, 2016
 70
Settlement of HSG contingent consideration liability for year ended December 31, 2017
 2,000
Settlement of PDA and LFT contingent consideration liability for year ended December 31, 20187,000
 
Contingent consideration liability from PDA and LFT acquisition on April 6, 2018
 (5,700)
Contingent consideration liability from MedPartners acquisition on April 9, 2018
 (4,400)
Contingent consideration liability from Silversheet acquisition on January 30, 2019(1,500) 
Contingent consideration liability from Advanced acquisition on June 14, 2019(10,622) 
Change in fair value of contingent consideration liability from PDA and LFT acquisition
 (1,213)
Change in fair value of contingent consideration liability from Medpartners acquisition700
 2,520
Change in fair value of contingent consideration liability from Silversheet acquisition1,500
 
Change in fair value of contingent consideration liability from Advanced acquisition(4,483) 
Balance as of September 30,$(15,105) $(8,793)
 20202019
Balance as of July 1,$(8,100)$(10,664)
Change in fair value of contingent consideration liability from Silversheet acquisition42 
Change in fair value of contingent consideration liability from Advanced acquisition(4,483)
Change in fair value of contingent consideration liability from b4health acquisition6,700 
Balance as of September 30,$(1,400)$(15,105)
20202019
Balance as of January 1,$(23,100)$(7,700)
Settlement of PDA and LFT contingent consideration liability for year ended December 31, 20180 7,000 
Settlement of Advanced contingent consideration liability for year ended December 31, 201920,000 0 
Contingent consideration liability from Silversheet acquisition on January 30, 2019(1,500)
Contingent consideration liability from Advanced acquisition on June 14, 2019(10,622)
Change in fair value of contingent consideration liability from MedPartners acquisition700 
Change in fair value of contingent consideration liability from Silversheet acquisition1,500 
Change in fair value of contingent consideration liability from Advanced acquisition(4,483)
Change in fair value of contingent consideration liability from b4health acquisition1,700 
Balance as of September 30,$(1,400)$(15,105)

The fair value measurements of contingent consideration liabilities classified as Level 3 in the fair value hierarchy include the following significant unobservable inputs:
 As of September 30, 2020As of December 31, 2019
Volatility75.0%50.0%
Discount rate12.9%16.5%
Risk-free rate0.1%1.5%
Cost of debt4.5%5.3%

Assets Measured on a Non-Recurring Basis
The Company applies fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to its goodwill, indefinite-lived intangible assets, long-lived assets, and equity investments.
The Company evaluates goodwill and indefinite-lived intangible assets annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. The Company determines the fair value of its reporting units based on a combination of inputs, including the market capitalization of the Company, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly. The Company determines the fair value of its indefinite-lived intangible assets using the income approach (relief-from-royalty method) based on Level 3 inputs.

18


The Company’s equity investment represents an investment in a non-controlled corporation without a readily determinable market value. The Company has elected to measure the investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes. The fair value is determined by using quoted prices for identical or similar investments of the same issuer, which are Level 2 inputs. The Company recognizes changes to the fair value of its equity investment in interest expense, net, and other in the condensed consolidated statements of comprehensive income.
The balance of the equity investment classified as Level 2 in the fair value hierarchy was $15,449 as of both September 30, 20192020 and December 31, 2018.2019. There were no changes to the fair value of the equity investment recognized during the three and nine months ended September 30, 2019.2020.
There were no triggering events identified, no indication of impairment of the Company’s goodwill, indefinite-lived intangible assets, long-lived assets, or equity investments, and 0 impairment charges recorded during the nine months ended September 30, 20192020 and 2018.2019.
Fair Value of Financial Instruments
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of September 30, 2019, the 5.125% Senior Notes due 2024 (the “2024 Notes”) have a carrying amount of $325,000 and an estimatedThe fair value of $337,188. As of December 31, 2018, the Company’s 2024 Notes had a carrying amount of $325,000 and an2027 Notes was estimated fair value of $310,375. Quotedusing quoted market prices in active markets for identical liabilities, based inputs (Level 1) were used to estimatewhich are Level 1 inputs. The carrying amounts and estimated fair value. Thevalue of the 2024 Notes were issuedand the 2027 Notes are presented in October 2016 and have a fixed rate of 5.125%.the following table. See additional information in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7)(8), Notes Payable and Credit Agreement” of our 2018the 2019 Annual Report.
As of September 30, 2020As of December 31, 2019
Carrying
Amount
Estimated
Fair Value
Carrying
Amount
Estimated
Fair Value
2024 Notes$325,000 $332,719 $325,000 $337,188 
2027 Notes500,000 511,875 300,000 301,500 
The fair value of the Company’s long-term self-insurance accruals cannot be estimated as the Company cannot reasonably determine the timing of future payments.


8. LEASES

The Company leases certain office facilities, data centers, and equipment under various operating leases. Leases with an initial term of 12 months or less (primarily related to housing arrangements for healthcare professionals on assignment) are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew, with renewal terms that can extend the lease term up to 10 years. Certain leases also include options to terminate the leases within 3 years.

The components of lease expense were as follows:
 Three Months Ended September 30, Nine Months Ended September 30,
 2019 2019
Lease Cost   
Operating lease cost$4,867
 $13,972
Short-term lease cost4,848
 15,846
Variable and other lease cost783
 2,099
Net lease cost$10,498
 $31,917


The maturity of lease liabilities as of September 30, 2019 were as follows: 
 Operating Leases
Years ending December 31, 
2019 (excluding the nine months ended September 30, 2019)$4,525
202018,343
202118,500
202218,230
202317,898
Thereafter50,379
Total lease payments$127,875
Less imputed interest(20,338)
Present value of lease liabilities$107,537


Supplemental cash flow information related to leases was as follows: 
 Nine Months Ended September 30,
 2019
Cash paid for amounts included in the measurement of operating lease liabilities (operating cash flows)$13,294
Operating lease right-of-use assets obtained in exchange for lease obligations$

Weighted average remaining lease term7 years
Weighted average discount rate4.8%



Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year) as of December 31, 2018 were as follows:
 Operating Leases
Years ending December 31,
2019$18,218
202018,149
202118,349
202218,144
202317,990
Thereafter50,436
Total minimum lease payments$141,286


Rent expense under operating leases (with initial lease terms in excess of one year) was $21,402 for the year ended December 31, 2018.

9. INCOME TAXES
The Company is subject to taxation in the U.S. and various states and foreign jurisdictions. With few exceptions, as of September 30, 2019,2020, the Company is no longer subject to state, local or foreign examinations by tax authorities for tax years before 20092010, and the Company is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2016. The IRS conducted, completed, and settled audits of the Company’s 2011-2012 and 2013 tax years related to income and employment tax issues for the Company’s treatment of certain non-taxable per diem allowances and travel benefits in November 2017 and May 2018, respectively. Prior to the Company'sCompany’s acquisition of Advanced, on June 14, 2019, Advanced was under an IRS audit for the years 2011-2013 for various payroll tax matters related to the treatment of certain non-taxable per diem allowances and travel benefits. This audit was completed and an assessment was issued for $8,300 in July 2018. Advanced filedThe Company received a protestfinal determination from the IRS in August 2018 and had their first IRS Appeals meeting in May 2019. Advanced is no longer subject to state or local examinations by tax authoritiesNovember 2019 for tax years before 2011. Advanced is no longer subject to U.S. federal income or payroll tax examinations for tax years before 2011 and, payroll and income tax examinations for the years 2014 and 2015.$1,300. The Company is indemnified by Advanced for the potential contingent liability for all pre-acquisition open years. The Company acquired Stratus Video on February 14, 2020. The Company is indemnified by Advanced.Stratus Video for any potential international income tax and contingent tax liability items for pre-acquisition open years up to $2,500. The Advanced acquisition isand Stratus Video acquisitions are more fully described in Note (2), “Acquisitions.”

The Company believes its indemnifications by Advanced and Stratus Video for all pre-acquisition years and its reserve for unrecognized tax benefits and contingent tax issues isare adequate with respect to all open years. Notwithstanding the foregoing, the Company could adjust its provision for income taxes and contingent tax liability based on future developments.

10.9. COMMITMENTS AND CONTINGENCIES: LEGAL PROCEEDINGS

From time to time, the Company is involved in various lawsuits, claims, investigations, and proceedings that arise in the ordinary course of business. These matters typically relate to professional liability, tax, compensation, contract, competitor disputes and employee-related matters and include individual and class action lawsuits, as well as inquiries and investigations by governmental agencies regarding the Company’s employment and compensation practices. Additionally, some of the Company’s clients may also become subject to claims, governmental inquiries and investigations, and legal actions relating to services provided by the Company’s healthcare professionals. Depending upon the particular facts and circumstances, the Company may also be subject to indemnification obligations under its contracts with such clients relating to these matters. The Company records a liability when management believes an adverse outcome from a loss contingency is both probable and the amount, or a range, can be reasonably estimated. Significant judgment is required to determine both probability of loss and the
19


estimated amount. The Company reviews its loss contingencies at least quarterly and adjusts its accruals and/or disclosures to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, or other new information, as deemed necessary. The most significant matters for which the Company has established loss contingencies are class actions related to wage and hour claims under California and Federal law. Specifically, among other claims in these lawsuits, it is alleged that employees were not afforded required breaks or compensated for all time worked, employees’ wage statements are not sufficiently clear and certain expense reimbursements should be considered wages and included in the regular rate of pay for purposes of calculating overtime rates. The Company believes that its wage and hour practices conform with the established law in all material respects, butrespects. However, litigation is always subject to inherent uncertainty.uncertainty, and the Company is not able to reasonably predict if any matter will be resolved in a manner that is materially adverse to the Company beyond the amounts accrued. In addition, for the matters for which it is at least reasonably possible that the estimated loss will change in the near term, the Company is unable to currently estimate the possible loss or range of loss beyond the amounts already accrued.
With regard to loss contingencies accrued as of September 30, 2019,2020, which are included in accounts payable and accrued expenses in the condensed consolidated balance sheets, the Company believes that such matters will not, either individually or

in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations, or cash flows.

20



11.10. BALANCE SHEET DETAILS

The consolidated balance sheets detail is as follows:
 September 30, 2019 December 31, 2018September 30, 2020December 31, 2019
Other current assets:    Other current assets:
Restricted cash and cash equivalents $16,885
 $26,329
Restricted cash and cash equivalents$15,194 $18,393 
Income tax receivable 4,200
 799
Income taxes receivableIncome taxes receivable5,984 
Other 16,280
 12,759
Other15,397 16,069 
Other current assets $37,365
 $39,887
Other current assets$30,591 $40,446 
    
Fixed assets:    Fixed assets:
Furniture and equipment $35,214
 $34,211
Furniture and equipment$45,807 $37,315 
Software 182,694
 162,006
Software210,735 191,050 
Leasehold improvements 9,296
 8,615
Leasehold improvements9,600 9,367 
 227,204
 204,832
266,142 237,732 
Accumulated depreciation (127,005) (114,413)Accumulated depreciation(153,390)(132,900)
Fixed assets, net $100,199
 $90,419
Fixed assets, net$112,752 $104,832 
    
Other assets:    Other assets:
Life insurance cash surrender value $74,645
 $55,028
Life insurance cash surrender value$87,485 $79,515 
Other 40,837
 41,124
Other38,346 40,739 
Other assets $115,482
 $96,152
Other assets$125,831 $120,254 
    
Accounts payable and accrued expenses:    Accounts payable and accrued expenses:
Trade accounts payable $25,474
 $31,537
Trade accounts payable$29,331 $26,985 
Subcontractor payable 61,958
 50,892
Subcontractor payable59,753 75,562 
Accrued expenses 35,125
 30,236
Accrued expenses44,240 36,344 
Loss contingencies 6,045
 24,549
Loss contingencies7,302 6,146 
Professional liability reserve 8,194
 8,633
Professional liability reserve9,104 7,925 
Other 2,709
 3,756
Other3,205 3,178 
Accounts payable and accrued expenses $139,505
 $149,603
Accounts payable and accrued expenses$152,935 $156,140 
    
Accrued compensation and benefits:    Accrued compensation and benefits:
Accrued payroll $43,727
 $42,571
Accrued payroll$51,016 $47,381 
Accrued bonuses 20,240
 18,021
Accrued bonuses27,833 22,613 
Accrued travel expense 2,529
 3,417
Accrued travel expense1,796 2,459 
Health insurance reserve 4,168
 3,559
Health insurance reserve5,537 4,019 
Workers compensation reserve 8,587
 7,817
Workers compensation reserve9,554 8,782 
Deferred compensation 75,739
 55,720
Deferred compensation87,934 81,064 
Other 2,960
 3,954
Other1,066 4,614 
Accrued compensation and benefits $157,950
 $135,059
Accrued compensation and benefits$184,736 $170,932 
    
Other current liabilities:    Other current liabilities:
Acquisition related liabilities $15,105
 $7,918
Acquisition related liabilities$1,400 $20,000 
Other 2,985

2,325
Other10,484 5,302 
Other current liabilities $18,090

$10,243
Other current liabilities$11,884 $25,302 
    
Other long-term liabilities:    Other long-term liabilities:
Workers compensation reserve $18,228
 $19,454
Workers compensation reserve$19,711 $18,291 
Professional liability reserve 34,855
 38,324
Professional liability reserve33,642 34,606 
Deferred rent 
 15,012
Unrecognized tax benefits 4,326
 4,862
Unrecognized tax benefits5,751 5,431 
Deferred revenue 383
 865
Other 1,864
 11
Other36,632 3,485 
Other long-term liabilities $59,656
 $78,528
Other long-term liabilities$95,736 $61,813 


21


12.11. SUBSEQUENT EVENTS

On October 1, 2019,20, 2020, the Company completed the issuance of $300,000$350,000 aggregate principal amount of the 20272029 Notes, which mature on October 1, 2027.April 15, 2029. Interest on the 20272029 Notes is payable semi-annually in arrears on April 115 and October 115 of each year, commencing April 1, 2020.15, 2021.

With the proceeds from the 20272029 Notes and cash generated from operations, the Company (1) redeemed the entire outstanding $325,000 aggregate principal amount of the 2024 Notes on November 4, 2020, (2) paid $9,857 consisting of the associated redemption premium and all accrued and unpaid interest on the 2024 Notes, (3) repaid $149,063 of existing Term Loan indebtedness, (2) repaid $146,000$40,000 under the Senior Credit Facility, and (3)(4) paid approximately $4,300$4,500 of fees and expenses related to the offering and issuance of the 20272029 Notes.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
 
The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018,2019, filed with the Securities and Exchange Commission (“SEC”) on February 21, 25, 2020 (“2019 (“2018 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.
Changes to Our Reportable Segments
Effective March 8, 2020, we modified our reportable segments. We previously utilized three reportable segments, which we identified as follows: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. In light of our acquisitions as well as our organizational changes to better align our structure with our strategy, our management reorganized our reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2020, we have disclosed the following three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The nurse and allied solutions segment includes our travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The physician and leadership solutions segment includes our locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes remote video interpreting, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. Prior period data in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been reclassified to conform to the new segment reporting structure.
Overview of Our Business
 
We provide healthcare workforce solutions and staffing services to healthcare facilitiesorganizations across the nation. As an innovative workforcetotal talent solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” workforce consulting services, remote video interpretation services, predictive modeling, staff scheduling, revenue cycle solutions and the placement of physicians, nurses, allied healthcare professionals and healthcare leaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.
We conduct business through three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. For the three months ended September 30, 2019,2020, we recorded revenue of $567.6$551.6 million, as compared to $526.8$567.6 million for the same period last year. For the nine months ended September 30, 2019,2020, we recorded revenue of $1,635.2$1,762.4 million, as compared to $1,607.4$1,635.2 million for the same period last year.
Nurse and allied solutions segment revenue comprised 63%71% and 61%70% of total consolidated revenue for the nine months ended September 30, 20192020 and 2018,2019, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all of the temporary nursing and allied staffing needs of a client and traditional clinical staffing solutions of variable assignment lengths. We also provide revenue cycle solutions, which includes skilled labor solutions for remote medical coding, clinical documentation improvement, case management, clinical data registry, and provides auditing and advisory services.
 
Locum tenensPhysician and leadership solutions segment revenue comprised 15%20% and 19%26% of total consolidated revenue for the nine months ended September 30, 20192020 and 2018,2019, respectively. Through our locum tenensphysician and leadership solutions segment, we provide
22


a comprehensive managed services solution in which we manage all of the locum tenens needs of a client and place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis as independent contractors. These locum tenens providers are used by our clients to fill temporary vacancies created by vacationWe also recruit physicians and leave scheduleshealthcare leaders for permanent placement and to bridge the gap while they seek permanent candidates or explore expansion. Our locum tenens clients represent a diverse group ofplace interim leaders and executives across all healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric facilities, government institutions, and insurance entities.settings. The interim healthcare professionals we place are recruited nationwide and are typically placed on contracts with assignment lengths ranging from a few days to one year.year, and a growing number of these placements are under our managed services solution.
 
OtherTechnology and workforce solutions segment revenue comprised 22%9% and 20%4% of total consolidated revenue for the nine months ended September 30, 20192020 and 2018,2019, respectively. Through our othertechnology and workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) identifying and recruiting physicians and healthcare leaders for permanent placement,language interpretation services, (2) placing interim leaders and executives across all healthcare settings, (3) a software-as-a-service (“SaaS”) VMS technologies through which our clients can manage their temporary staffing needs, (3) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, (4) RPO services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, (5) an education program that provides custom healthcare education, research, professional practice tools,credentialing services, and professional development services, (6) revenue cycle solutions and related consulting services, (7)

workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, and (8) credentialingflex pool management services.

As part of our long-term growth strategy to add value for our clients, healthcare professionals, and shareholders, on February 14, 2020, December 19, 2019, June 14, 2019, and January 30, 2019, April 9, 2018 and April 6, 2018, we acquired Stratus Video, b4health, Advanced, and Silversheet, MedPartners HIM (“MedPartners”),respectively. Stratus Video is a remote video interpreting company that provides healthcare interpretation via remote video, over the phone, and Phillips DiPisaonsite in-person, supported by proprietary technology platforms. b4health is an innovative technology company providing a web-based internal float pool management solution and Leaders For Today (“PDA” and “LFT”), respectively.vendor management system for healthcare facilities. Advanced is a national healthcare staffing company that specializes in placing therapists and nurses across multiple settings, including hospitals, schools, clinics, skilled nursing facilities, and home health. Silversheet provides innovative credentialing software solutions to clinicians and healthcare enterprises. MedPartners provides revenue cycle solutions, including case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. PDA and LFT offer a range of leadership staffing and permanent placement solutions for the healthcare industry. See additional information in the accompanying Note (2), “Acquisitions.”
Recent Trends

Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends. The U.S. BureauDuring the first few months of Labor Statistics’ survey data reflects near record levels of healthcare job openings and quits. We view this data, along with a nearly 20-year-low unemployment rate and continued economic growth as2020, the positive trends for the healthcare staffing industry. These positive macro economicmacroeconomic and labor trends have created a highly competitive market for healthcare professionals. However, when the imposition of “shelter-in-place” orders and the suspension of elective and “non-essential” healthcare services occurred in March 2020 in response to the COVID-19 health crisis, demand for many of our businesses declined significantly. Although most of these “shelter-in-place” orders and service suspensions have been loosened and lifted, general utilization of healthcare continues to be below the pre-COVID-19 levels, which continues to negatively impact demand for many of our business lines other than nursing, certain allied disciplines, language interpretation services and our vendor management technology solutions. At the same time, demand for our nursing services has fluctuated significantly throughout the nine months of the year based on COVID-19 related needs and is currently at a historically high level. With the uncertainty regarding safety concerns, the increase in unemployment, related economic concerns and the uncertainty surrounding the COVID-19 pandemic, we are unable to predict the extent and duration to which demand for our businesses will continue to be impacted by the COVID-19 pandemic.

In our nurse and allied solutions segment, prior to the COVID-19 pandemic, our ability to recruit enough nurses to meet the then-current demand levels was impacted by the tight labor market and modest bill rate increases. Starting in early March, and in response to the COVID-19 public health crisis, bill rates and wages for cliniciansnurses increased significantly in order to attract nurses to higher risk positions. In the latter part of April, we experienced a significant cancellation of requests for nurses as hospitalization rates from COVID-19 were initially well below originally expected levels in most areas of the US other than the northeast. In May and early June, with the decrease in COVID-19 related requests coupled with the lower healthcare utilization overall, demand in our clinician supply, particularlynursing businesses dropped well below prior year levels, and bill rates started trending back towards standard rate levels. Starting in late-June, as COVID-19 infection rates and hospitalizations significantly increased across many areas of the country, demand for nurses rose quickly, and total demand for nursing has not kept paceexceeded prior year levels since mid-July and is currently at record levels. Demand for nurses in specialties including ICU, telemetry, and medical surgical nurses is particularly strong, and needs are high across the country. With the higher demand, and urgent need to quickly fill positions, bill rates and wages for these nurses are currently well above prior year levels. Although the number of nurses on travel assignments has been increasing each month since the lowest point in July, our ability to adequately meet the high client demand is constrained by the tight labor market along with growthnurse burnout and other issues related to the pandemic. In addition, as a result of the significant increase in client demand.COVID-19 infection and hospitalization rates throughout the third quarter and into October, our workers’ compensation insurance costs have increased.

The consolidation withinallied staffing division is also seeing record demand, but this demand significantly varies by discipline. We have seen a significant increase in demand for respiratory therapists and lab technicians due to the high COVID-19 infections and
23


hospitalizations across the country. Demand for our imaging and lab specialties has steadily recovered and is now above prior year levels. For speech language therapists contracted to work with schools, the uneven levels of in-person education has slowed in growth, but this slowdown in growth has been partially mitigated by the fact that many therapists have been able to deliver care through the adoption of our teletherapy platform. Prior to the COVID-19 public health crisis, our allied staffing division experienced a decline in demand for physical therapists from skilled nursing facility and home health clients resulting from recently implemented Medicare reimbursement changes. This decline in demand was further exacerbated by the impact of COVID-19 in March. Although the utilization of physical therapists has been slowly increasing with the general recovery in healthcare, industrydemand and placements for this discipline are still well below prior year.

In our physician and leadership solutions segment, our locum tenens division started the year well, with recruiter productivity and revenue increasing after disruptions resulting from process and technology changes made during 2018. However, in mid-March, as a result of COVID-19, our locum tenens business experienced a significant increase in order cancellations and a decrease in overall demand due to the suspension of elective procedures and non-essential healthcare services. With healthcare utilization resuming in late April, demand and placements for locum tenens has been slowly improving, but the recovery is creating larger, more sophisticatedinconsistent across specialties.

For our interim leadership division, demand decreased as providers reacted to lower patient volumes and complexfocused on cost containment. Our physician permanent placement and healthcare executive search businesses experienced a decline in overall search demand as many clients have temporarily suspended filling open roles due to uncertainty from the COVID-19 public health systems that we believecrisis. Since June, demand for our interim and permanent placement services has elevated the need for strategicimproved from their lowest levels, but clients remain cautious in hiring in this uncertain environment.

In our technology and workforce solutions capablesegment, our VMS technologies initially experienced increased growth following the outbreak of partneringthe COVID-19 public health crisis as clients utilized our technologies to solveeffectively manage their recruiting, staffingincreased demand for nurses. As demand for nurses declined during the quarter, utilization of the VMS technologies also declined. However, more recently, orders and workforce optimization requirements. Givenplacements in the increasing needtechnologies have risen again, and new clients are also adopting the platforms to engage with contingent labor.

In early March, the utilization in our language interpretation business declined as a result of the COVID-19-related suspension or restriction of elective and “non-essential” healthcare services. However, utilization started to increase in late April as many of these restrictions were lifted and healthcare utilization resumed more normal activities. By mid-June, weekly interpretation minutes utilized were above pre-COVID-19 levels and have continued to steadily increase from both existing and new clients.

At the onset of the COVID-19 pandemic, we experienced a delay in discussions with clients regarding new contracts or expansions. As clients have recently begun to resume normal operations, we have contracted for partners capable of offering a comprehensive workforce solution, we continue to see the benefits of our workforce solutions strategy, particularly with our MSPs.several new managed services programs and service line expansions. As a result of our ongoing focus on these types of strategic MSP relationships, the percentage of our staffing revenue derived from our MSP clients continues to increase,increase.

In response to the reduced demand for services as a result of the COVID-19 pandemic, throughout the second quarter, we took actions to reduce our selling, general and we believe these strategic, longer-term relationships willadministrative expenses. Cost reduction actions taken included, among other things, suspending employer contributions under our 401(k) retirement savings plan and deferred compensation plan, reducing our workforce to correspond to reduced demand, and reducing variable compensation, travel, professional services and marketing expenses. As our businesses continue to comprise a greater proportion of revenue in our staffing businesses.

In our nurse and allied solutions segment, overall demand is strong and at the highest levels seen since 2016. However, placement activity has been unfavorably impacted by fewer contingent nurse staffing needs from a large client. Additionally, a tight labor market and modest growth in bill rates is also impacting our ability to sufficiently recruit the nurses to meet the increased demand. Our allied staffing business continues to have strong overall demand resulting in steady organic revenue growth. However,recover, we have recently experienced a declinebeen selectively increasing our workforce, increasing spending in demand for therapists from our skilled nursing facility clients that is resulting from recently implemented Medicare reimbursement changes. The access to additional supply of nursecertain areas and allied healthcare professionals fromrestoring certain benefits, although overall expenses are still well below the Advanced acquisition has helped us better address our client’s staffing demands.levels before COVID-19.

The demand environment for locum tenens is also generally favorable, although demand for hospitalists and emergency room physicians has significantly declined over the past 12 months. Our locum tenens business has stabilized after disruption resulting from process and technology changes made during 2018, and recruiter productivity continues to improve.

In our other workforce solutions segment, better demand and placements in the interim leadership and physician permanent placement divisions and growth in technology workforce solutions are driving improved segment performance and our profitability on a consolidated basis. Since experiencing a decline in our revenue cycle solutions revenue in recent quarters, revenue for this division has seen signs of stabilization due in part to growing opportunities to serve our MSP customers.

Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate

our estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates, other than the adoption of the Accounting Standards UpdateUpdates (“ASU”ASUs”) 2016-02 described in Item 1. Condensed Consolidated Financial
24


Statements—Note 1, “Basis of Presentation,” as compared to the critical accounting policies and estimates described in our 20182019 Annual Report.
 
Results of Operations
The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) locum tenensphysician and leadership solutions, and (3) othertechnology and workforce solutions. The PDA, LFT, MedPartners, Silversheet, Advanced, b4health and AdvancedStratus Video acquisitions impact the comparability of the results between the three and nine months ended September 30, 20192020 and 20182019 depending on the timing of the applicable acquisition. Our historical results are not necessarily indicative of our future results of operations.
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Unaudited Condensed Consolidated Statements of Operations:
Revenue100.0 %100.0 %100.0 %100.0 %
Cost of revenue66.5 66.5 66.9 66.6 
Gross profit33.5 33.5 33.1 33.4 
Selling, general and administrative20.2 23.5 22.4 22.9 
Depreciation and amortization4.9 3.0 3.9 2.6 
Income from operations8.4 7.0 6.8 7.9 
Interest expense, net, and other2.3 1.4 1.9 1.1 
Income before income taxes6.1 5.6 4.9 6.8 
Income tax expense1.4 1.5 1.4 1.5 
Net income4.7 %4.1 %3.5 %5.3 %
 Three Months Ended September 30, Nine Months Ended September 30,
 2019 2018 2019 2018
Unaudited Condensed Consolidated Statements of Operations:       
Revenue100.0% 100.0% 100.0% 100.0%
Cost of revenue66.5
 66.8
 66.6
 67.4
Gross profit33.5
 33.2
 33.4
 32.6
Selling, general and administrative23.5
 23.0
 22.9
 21.2
Depreciation and amortization3.0
 2.1
 2.6
 1.9
Income from operations7.0
 8.1
 7.9
 9.5
Interest expense, net, and other1.4
 0.9
 1.1
 1.0
Income before income taxes5.6
 7.2
 6.8
 8.5
Income tax expense1.5
 1.9
 1.5
 1.9
Net income4.1% 5.3% 5.3% 6.6%


 
Comparison of Results for the Three Months Ended September 30, 20192020 to the Three Months Ended September 30, 20182019
 
RevenueRevenue increased 8%decreased 3% to $567.6$551.6 million for the three months ended September 30, 20192020 from $526.8$567.6 million for the same period in 2018,2019, primarily attributable to additional revenue of $37.0 million from our Silversheet and Advanced acquisitions and higher organiclower revenue in our physician and leadership solutions and nurse and allied solutions segment,segments, partially offset by loweradditional revenue inof $36.6 million from our locum tenens solutions segment.b4health and Stratus Video acquisitions. Excluding the additional revenue from acquisitions, revenue increased 1%decreased 9%.
Nurse and allied solutions segment revenue increased 18%decreased 4% to $362.5$382.7 million for the three months ended September 30, 20192020 from $306.3$398.4 million for the same period in 2018.2019. The $56.2$15.7 million increasedecrease was primarily attributable to $36.6 million of revenue in connection with the Advanced acquisition, a 2% increase20% decrease in the average number of healthcare professionals on assignment, and a 2%partially offset by an approximately 15% increase in the average bill rate during the duringthree months ended September 30, 2020.
Physician and leadership solutions segment revenue decreased 24% to $109.1 million for the three months ended September 30, 2019.
Locum tenens solutions segment revenue decreased 17% to $84.22020 from $143.8 million for the three months ended September 30, 2019 from $101.1 million for the same period in 2018.2019. The $16.9$34.7 million decrease was primarily attributable to a 15%16% decrease in the number of days filled and a 2%4% decrease in the revenue per day filled in our locum tenens business, which was attributable to the continued impact of COVID-19 since the second half of March of 2020, during the three months ended September 30, 2019.2020. In addition, revenue in our interim leadership and permanent placement businesses declined during the three months ended September 30, 2020 due to a decrease in overall demand as some clients continued to place new searches on hold due to the COVID-19 public health crisis.
OtherTechnology and workforce solutions segment revenue increased 1%136% to $120.9$59.8 million for the three months ended September 30, 20192020 from $119.4$25.3 million for the same period in 2018.2019. The $1.5$34.5 million increase was primarily attributable to growth inadditional revenue of $36.6 million from our interim leadership, permanent placement, recruitment process outsourcing,b4health and VMS businesses, partially offset by a decline in our revenue cycle solutions businessStratus Video acquisitions during the three months ended September 30, 2019.2020.
For the three months ended September 30, 2020 and 2019, revenue under our MSP arrangements comprised approximately 49% and 43% of our consolidated revenue, 67% and 54% for nurse and allied solutions segment revenue and 16% and 20% for physician and leadership solutions segment revenue, respectively.

Gross Profit. Gross profit increased 8%decreased 3% to $190.0$184.6 million for the three months ended September 30, 2019 from $175.1 million for the same period in 2018, representing gross margins of 33.5% and 33.2%, respectively. The gross margin for the three months ended September 30, 2020 from $190.0 million for the same period in 2019, representing gross margins of 33.5% and 33.5%, respectively. Consolidated gross margin
25


for the three months ended September 30, 2020, as compared to the same period in 2019, was positivelyprimarily impacted by a higherlower gross margin in our nurse and allied solutions segment, driven primarily by a higher labor disruption marginworkers’ compensation and partiallyhealth insurance expenses due to the COVID-19 pandemic, which was offset by the change in sales mix resulting from our b4health and Stratus Video acquisitions and their higher traveler housing costs, and higher other workforce solutions gross margin. These positive factors were partially offset by a lower margin inmargins as compared to our locum tenens solutions segment and an unfavorable segment mix shift.staffing businesses. Gross margin by reportable segment for the three months ended September 30, 2020 and 2019 was 27.4% and 2018 was 27.9% and 27.4%28.5% for nurse and allied solutions, 27.5%36.7% and 28.4%36.8% for locum tenensphysician and leadership solutions, and 54.3%66.1% and 52.4%93.0% for othertechnology and workforce solutions, respectively. The year-over-year gross margin decline in the locum tenenstechnology and workforce solutions segment was driven byprimarily due to the change in sales mix resulting from the addition of lower perm conversion fees.margin Stratus Video as compared to our SaaS-based technologies within the segment.
 

Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A”) expenses were $133.2$111.2 million, representing 23.5%20.2% of revenue, for the three months ended September 30, 2019,2020, as compared to $121.2$133.2 million, representing 23.0%23.5% of revenue, for the same period in 2018.2019. The increasedecrease in SG&A expenses was primarily due to $6.8cost reduction measures that were initiated during the second quarter of 2020 and a $10.3 million of additional SG&A expenses from the Silversheet and Advanced acquisitions, a $10.1 million increasedecrease related to acquisition, integration, changes in the fair value of earn-out liabilities from acquisitions, restructuring, and extraordinary legal expenses, higher employee compensation expenses, and other expenses associated with our revenue growth.expenses. The increaseoverall decrease was partially offset by a $12.1$5.7 million increase in legal accruals duringof additional SG&A expenses from the three months ended September 30, 2018.b4health and Stratus Video acquisitions. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:      
(In Thousands)
(In Thousands)
Three Months Ended September 30,
Three Months Ended September 30,
2019 2018 20202019
Nurse and allied solutions$53,673
 $41,643
Nurse and allied solutions$52,067 $60,925 
Locum tenens solutions16,998
 17,762
Other workforce solutions37,854
 33,575
Physician and leadership solutionsPhysician and leadership solutions24,537 35,455 
Technology and workforce solutionsTechnology and workforce solutions14,369 12,145 
Unallocated corporate overhead21,857
 26,427
Unallocated corporate overhead16,490 21,857 
Share-based compensation2,825
 1,809
Share-based compensation3,772 2,825 
$133,207
 $121,216
$111,235 $133,207 
Depreciation and Amortization Expenses. Amortization expense increased 70%72% to $11.4$19.6 million for the three months ended September 30, 20192020 from $6.7$11.4 million for the same period in 2018,2019, primarily attributable to additional amortization expenses related to the intangible assets acquired in the Silversheetb4health and AdvancedStratus Video acquisitions and the shortened useful lifelives of the tradename intangible asset acquired inassets during the MedPartners acquisition.third quarter of 2020. Depreciation expense increased 24%28% to $5.7$7.3 million for the three months ended September 30, 20192020 from $4.6$5.7 million for the same period in 2018,2019, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.
Interest Expense, Net, and OtherInterest expense, net, and other, was $7.8$12.6 million during the three months ended September 30, 20192020 as compared to $4.6$7.8 million for the same period in 2018.2019. The increase is primarily due to a higher average debt outstanding balance for the three months ended September 30, 2019,2020, which resulted from (1) borrowings under our Amended Credit Agreement (as defined below in this Item 2) used to finance the SilversheetStratus Video acquisition, (2) the issuance of our Existing 2027 Notes (as defined below in this Item 2) in October 2019, and Advanced acquisitions,(3) the issuance of our New 2027 Notes (as defined below in this Item 2) in August 2020. The proceeds from the issuances of the higher interest bearing senior notes were used to repay, in whole in the fourth quarter of 2019 and a $1.4 million gain related toin part in the changethird quarter of 2020, our indebtedness under the Credit Facilities (as defined below in fair value of an equity investment during the three months ended September 30, 2018. The overall increase is partially offset by a higher income from restricted investments related to our captive insurance company for the three months ended September 30, 2019.this Item 2).

Income Tax Expense. Income tax expense was $8.4$7.8 million for the three months ended September 30, 20192020 as compared to $10.1$8.4 million for the same period in 2018,2019, reflecting effective income tax rates of 26%23% and 27%26% for the three months ended September 30, 20192020 and 2018,2019, respectively. The decrease in the effective income tax rate was primarily attributable to the Company’srecognition of a $1.6 million discrete tax benefits of $1.5 million and $0.9 million in relation to income before income taxes of $31.9 million and $38.0 millionbenefit for the three months ended September 30, 2019 and 2018, respectively. We currently estimate our annual effective tax rate to be approximately 24% for 2019. The 26% effective tax rate for the three months ended September 30, 2019 differs from our estimated annual effective tax rate of 24% primarily due to less proportionate discrete tax benefits recorded during the three months ended September 30, 2019, as compared to the nine months ended September 30, 2019, in relation to income before income taxes. The discrete tax benefits are related to equity awards vested and exercised and fair value changes in the cash surrender value of our Company Owned Life Insurance (“COLI”) during the three months ended September 30, 2020 compared to a $0.2 million discrete tax benefit for COLI during the same period in 2019, in relation to income before income taxes of $33.9 million and reductions$31.9 million for the three months ended September 30, 2020 and 2019, respectively. We currently estimate our annual effective tax rate to be approximately 29% for 2020. The 23% effective tax rate for the three months ended September 30, 2020 differs from our estimated annual effective tax rate of 29% primarily due to the reservediscrete tax benefits for unrecognized tax benefits.COLI and shared-based compensation recognized during the three months ended September 30, 2020, in relation to income before income taxes.

Comparison of Results for the Nine Months Ended September 30, 20192020 to the Nine Months Ended September 30, 20182019
 
26


RevenueRevenue increased 2%8% to $1,635.2$1,762.4 million for the nine months ended September 30, 20192020 from $1,607.4$1,635.2 million for the same period in 2018,2019, primarily attributable to additional revenue of $76.7$154.4 million from our PDA, LFT, MedPartners, Silversheet, Advanced, b4health, and AdvancedStratus Video acquisitions and higher organic revenue in our nurse and allied solutions segment, partially offset by an approximately $8.0 million decrease in labor disruption revenue and lower revenue in our locum tenensphysician and leadership solutions segment. Excluding the additional revenue from acquisitions, revenue decreased 3%2%.
Nurse and allied solutions segment revenue increased 6%10% to $1,031.2$1,251.5 million for the nine months ended September 30, 20192020 from $977.2$1,139.9 million for the same period in 2018.2019. The $54.0$111.6 million increase was primarily attributable to additional revenue of $41.7$72.2 million in connection with the Advanced acquisition. Excluding the impact from the Advanced acquisition, andthe increase was also attributable to an approximately 14% increase in the average bill rate, partially offset by a 1% increase12% decrease in the average number of healthcare

professionals on assignment and an approximately $15.0 million decrease in labor disruption revenue during the nine months ended September 30, 2019, partially offset by an approximately $8.0 million decrease in labor disruption revenue.2020.
Locum tenensPhysician and leadership solutions segment revenue decreased 21%16% to $246.7$355.6 million for the nine months ended September 30, 20192020 from $311.5$423.4 million for the same period in 2018.2019. The $64.8$67.8 million decrease was primarily attributable to a 21%13% decrease in the number of days filled during the nine months ended September 30, 2019, partially offset by2020 and a slight increase3% decrease in the revenue per day filled.filled in our locum tenens business. In addition, revenue in our interim leadership and permanent placement businesses declined during the nine months ended September 30, 2020 due to a decrease in overall demand as some clients placed new searches on hold due to the COVID-19 public health crisis.
OtherTechnology and workforce solutions segment revenue increased 12%116% to $357.3$155.4 million for the nine months ended September 30, 20192020 from $318.7$72.0 million for the same period in 2018.2019. Of the $38.6$83.4 million increase, $35.1$82.2 million was attributable to additional revenue in connection with the PDA, LFT, MedPartners,from our Silversheet, b4health and SilversheetStratus Video acquisitions with the remainder primarily attributable to growth in our permanent placement, recruitment process outsourcing, VMS, and organic interim leadership businesses, partially offset by a decline in our organic revenue cycle solutions business during the nine months ended September 30, 2019.2020.
For the nine months ended September 30, 2020 and 2019, revenue under our MSP arrangements comprised approximately 49% and 46% of our consolidated revenue, 65% and 58% for nurse and allied solutions segment revenue and 17% and 20% for physician and leadership solutions segment revenue, respectively.
 
Gross Profit. Gross profit increased 4%7% to $546.3$584.2 million for the nine months ended September 30, 20192020 from $523.9$546.3 million for the same period in 2018,2019, representing gross margins of 33.4%33.1% and 32.6%33.4%, respectively. The decline in consolidated gross margin for the nine months ended September 30, 20192020 was positively impacted byprimarily due to a higherlower gross marginsmargin in our nurse and allied solutions segment, driven primarily by lower bill-to-pay spreads and higher labor disruption margin, higher other workforce solutions gross margin, a change in our physician permanent placement business model that prompted a $4.3 million classification of certain recruiterworkers’ compensation insurance expenses due to SG&A that was previously in cost of revenue, and a favorable segment mix shift. These positive factors werethe COVID-19 pandemic, partially offset by a lower marginthe change in sales mix resulting from our locum tenens solutions segment.b4health and Stratus Video acquisitions and their higher margins as compared to our staffing businesses. Gross margin by reportable segment for the nine months ended September 30, 2020 and 2019 was 27.6% and 2018 was 27.8% and 27.2%28.3% for nurse and allied solutions, 27.7%36.6% and 29.0%36.9% for locum tenensphysician and leadership solutions, and 53.7%69.5% and 52.6%93.0% for othertechnology and workforce solutions, respectively. The year-over-year gross margin decline in the locum tenenstechnology and workforce solutions segment was driven byprimarily due to the change in sales mix resulting from the addition of lower perm conversion fees and lower bill-to-pay spreads.margin Stratus Video as compared to our SaaS-based technologies within the segment.
 
Selling, General and Administrative Expenses. SG&A expenses were $374.9$394.5 million, representing 22.9%22.4% of revenue, for the nine months ended September 30, 2019,2020, as compared to $341.5$374.9 million, representing 21.2%22.9% of revenue, for the same period in 2018.2019. The increase in SG&A expenses was primarily due to $17.8$24.4 million of additional SG&A expenses from the PDA, LFT, MedPartners, Silversheet, Advanced, b4health, and AdvancedStratus Video acquisitions, a $17.3$6.9 million increase related to acquisition, integration, changes in the fair value of earn-out liabilities from acquisitions, restructuring, and extraordinary legal expenses, a $3.8 million increase in share-based compensation expense, and higher employee compensation expenses. The increase was partially offset by an additional $3.5 million oflower favorable actuarial-based decreasesdecrease in our professional liability reserves as compared to the same period in 20182019, and a $12.1$3.3 million increase in legal accrualsshare-based compensation expense. The increase was partially offset by cost reduction measures that were initiated during the nine months ended September 30, 2018.second quarter of 2020. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:      
(In Thousands)
(In Thousands)
Nine Months Ended September 30,
Nine Months Ended September 30,
2019 2018 20202019
Nurse and allied solutions$142,196
 $128,107
Nurse and allied solutions$172,256 $164,308 
Locum tenens solutions49,281
 55,930
Other workforce solutions110,589
 90,226
Physician and leadership solutionsPhysician and leadership solutions84,820 103,950 
Technology and workforce solutionsTechnology and workforce solutions46,192 33,808 
Unallocated corporate overhead61,093
 59,271
Unallocated corporate overhead76,223 61,093 
Share-based compensation11,713
 7,954
Share-based compensation15,046 11,713 
$374,872
 $341,488
$394,537 $374,872 
27


Depreciation and Amortization Expenses. Amortization expense increased 44%89% to $25.4$48.1 million for the nine months ended September 30, 20192020 from $17.6$25.4 million for the same period in 2018,2019, with the increase primarily attributable to additional amortization expenses related to the intangible assets acquired in the PDA, LFT, MedPartners, SilversheetAdvanced, b4health and AdvancedStratus Video acquisitions, and the shortened useful life of the tradename intangible asset acquired in the MedPartners acquisition.acquisition, which occurred during the third quarter of 2019, and the shortened useful lives of tradename intangible assets during the third quarter of 2020. Depreciation expense increased 32%30% to $16.1$21.0 million for the nine months ended September 30, 20192020 from $12.2$16.1 million for the same period in 2018,2019, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.
Interest Expense, Net, and OtherInterest expense, net, and other, was $19.6$35.1 million during the nine months ended September 30, 20192020 as compared to $16.4$19.6 million for the same period in 2018.2019. The increase is primarily due to a higher average debt outstanding balance for the nine months ended September 30, 2019,2020, which resulted from (1) borrowings under our Amended Credit Agreement (as defined below in this Item 2) used to finance the SilversheetStratus Video and Advanced acquisitions, (2) the issuance of our Existing 2027 Notes (as defined below in this Item 2) in October 2019, and a $1.4 million gain related(3) the issuance of our New 2027 Notes (as defined below in this Item 2) in August 2020. The proceeds from the issuances of the higher interest bearing senior notes were used to repay, in whole in the changefourth quarter of 2019 and in fair valuepart in the third quarter of an equity

investment during2020, our indebtedness under the nine months ended September 30, 2018. The overall increase is partially offset by higher income from restricted investments related to our captive insurance company for the nine months ended September 30, 2019.Credit Facilities (as defined below in this Item 2).
Income Tax Expense. Income tax expense was $23.9$24.2 million for the nine months ended September 30, 20192020 as compared to income tax expense of $30.2$23.9 million for the same period in 2018,2019, reflecting effective income tax rates of 22%28% and 22% for these periods, respectively. The increase in the effective income tax rate was primarily attributable to the recognition of discrete tax benefits of $2.9 million and $9.8 million in relation to income before income taxes of $85.5 million and $110.4 million for the nine months ended September 30, 2020 and 2019, respectively. We currently estimate our annual effective income tax rate to be approximately 24%29% for 2019. The 22% effective tax rate for the nine months ended September 30, 2019 differs from our estimated annual effective income tax rate of 24% due to lower income before income taxes for the nine months ended September 30, 2019 compared to projected income before income taxes for the twelve months ended December 31, 2019 in proportion to the same amount of discrete tax benefits for both periods.2020.

Liquidity and Capital Resources
 
In summary, our cash flows were:

(In Thousands)
 Nine Months Ended September 30,
 20202019
Net cash provided by operating activities$216,981 $146,205 
Net cash used in investing activities(528,458)(253,606)
Net cash provided by financing activities266,557 136,440 
 (In Thousands)
Nine Months Ended September 30,
 2019 2018
  
Net cash provided by operating activities$146,205
 $168,046
Net cash used in investing activities(253,606) (271,648)
Net cash provided by financing activities136,440
 81,774
Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities. As of September 30, 2019,2020, (1) the total of our Additional Term Loan (as defined below) outstanding (including both current and long-term portions) was $149.1$46.9 million, (2) $146.0$40.0 million was drawn with $239.3$338.1 million of available credit under the Senior Credit Facility (as defined below), and (3) the aggregate principal amount of our 5.125% Senior Notes due 2024 (the “2024 Notes”) outstanding equaled $325.0 million and (4) the aggregate principal amount of our the 2027 Notes (as defined below) outstanding equaled $500.0 million. We describe in further detail our credit agreement, in effect prior to the second amendment thereof, under which our Senior Credit Facility is governed, the 2024 Notes, and the 20242027 Notes in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7)(8), Notes Payable and Credit Agreement” of our 20182019 Annual Report on Form 10-K.Report. See additional information on our Amended Credit Agreement (as defined below) and the New 2027 Notes (as defined below) in Note (6), “Notes Payable and Credit Agreement” to the accompanying Condensed Consolidated Financial Statements.
We believe that cash generated from operations and available borrowings under our Senior Credit Facility will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under our Senior Credit Facility or other borrowings under our Amended Credit Agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.
 
28


Operating Activities
 
Net cash provided by operating activities for the nine months ended September 30, 20192020 was $146.2$217.0 million, compared to $168.0$146.2 million for the same period in 2018.2019. The decreaseincrease in net cash provided by operating activities was primarily attributable to (1) an increase in other liabilities between periods of $36.9 million, and a corresponding decrease in income tax receivable between periods of $9.6 million, primarily due to our election to defer estimated income tax payments and employer payroll taxes in accordance with the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was partially offset by the contingent consideration earn-out payment for the Advanced acquisition (in excess of its acquisition-date fair value, which is noted below in financing activities), (2) a decrease in accounts receivable and subcontractor receivable between periods of $19.0 million due to improved collections and a decrease in associate vendor usage, (3) an increase in accounts payable and accrued expenses between periods of $8.8 million primarily due to the payment of a loss contingency during the second quarter of 2019, (4) a decrease in other assets between periods of $12.2 million due to lower long-term prepayments and increases in subcontractor receivables, income tax receivable, and other assets.deposits. The overall decreaseincrease was partially offset by a decrease in accounts receivable and increases in accrued compensation and benefits and other liabilities between periods of $12.2 million primarily due to timing of payments.lower employee contributions to the deferred compensation plan as compared to the prior year. Our Days Sales Outstanding (“DSO”) was 59 days at September 30, 2020, 55 days at December 31, 2019, and 57 days at September 30, 2019, 64 days at December 31, 2018, and 64 days at September 30, 2018.2019.
 
Investing Activities
 
Net cash used in investing activities for the nine months ended September 30, 2020 was $528.5 million, compared to $253.6 million for the same period in 2019. The increase was primarily due to (1) $476.5 million used for acquisitions during the nine months ended September 30, 2020, as compared to $228.2 million during the nine months ended September 30, 2019, was $253.6 million, compared to $271.6 million for the same period in 2018. The decrease was primarily due to and (2) a net proceedspurchase of restricted investments related to our captive insurance company of $15.9 million during the nine months ended September 30, 2020, as compared to net proceeds of $11.9 million during the nine months ended September 30, 2019, as comparedwhich is primarily due to a net purchasestrategic planning of $16.8 million during the nine months ended September 30, 2018. The decrease was partially offset by $228.2 million used for acquisitions during the nine months ended September 30, 2019, as compared to $217.4 million used for acquisitions during the nine months ended September 30, 2018. See additional informationinvesting in the accompanying Note (2),

“Acquisitions.” Capitallonger maturities. In addition, capital expenditures were $24.8$27.4 million and $23.9$24.8 million for the nine months ended September 30, 20192020 and 2018,2019, respectively.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2020 was $266.6 million, primarily due to (1) borrowings of $245.0 million under the Senior Credit Facility (as defined below) and $250.0 million under the Additional Term Loan (as defined below), which were primarily used to fund our Stratus Video acquisition, and (2) $202.0 million of gross proceeds received in connection with the issuance of the New 2027 Notes (as defined below), partially offset by (1) the repayments of $205.0 million under the Senior Credit Facility and $203.1 million under the Additional Term Loan, (2) $10.6 million for acquisition contingent consideration earn-out payments, (3) $4.8 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards, and (4) $6.9 million payment of financing costs in connection with the Amended Credit Agreement (as defined below) and the issuance of the New 2027 Notes. Net cash provided by financing activities during the nine months ended September 30, 2019 was $136.4 million, primarily due to borrowings of $101.0 million under the Senior Credit Facility (as defined below) and $150.0 million of borrowings under the Term Loan (as defined below) used to fund our Advanced acquisition, partially offset by (1) the repayment of $75.0 million under the Senior Credit Facility, (2) $18.7 million paid in connection with the repurchase of our common stock, (3) $5.7 million for acquisition contingent consideration earn-out payments, and (4) $13.3 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards. Net cash provided by financing activities during the nine months ended September 30, 2018 was $81.8 million, primarily due to borrowings of $195.0 million under the Senior Credit Facility, partially offset by (1) the repayment of $45.0 million under the Senior Credit Facility, (2) $52.8 million paid in connection with the repurchase of common stock, (3) $2.3 million payment of financing costs in connection with the new credit agreement, (4) $1.7 million for acquisition contingent consideration earn-out payments, and (5) $11.4 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.

Amended Credit Agreement

On February 9, 2018, we entered into a credit agreement (the “New Credit Agreement”) with several lenders to provide for a $400.0 million secured revolving credit facility (the “Senior Credit Facility”) to replace our then-existing credit agreement. The Senior Credit Facility includes a $50.0 million sublimit for the issuance of letters of credit and a $50.0 million sublimit for swingline loans. On June 14, 2019, we entered into the first amendment to the New Credit Agreement (the “First Amendment”) to provide for, among other things, a $150.0 million secured term loan credit facility (the “Term Loan”). On February 14, 2020, we entered into the second amendment to the New Credit Agreement (the “Second Amendment”) to provide for, among other things, a $250.0 million secured term loan credit facility (the “Additional Term Loan” and, together with the Senior Credit Facility, the “Credit Facilities”). The FirstSecond Amendment (together with the New Credit Agreement and the First Amendment, collectively, the “Amended Credit Agreement”) also extended the maturity date of the Senior Credit Facility to be coterminous with the Additional Term Loan. Our obligations under the Amended Credit Agreement are secured by substantially all of our assets. For more detail regarding the terms of the Amended Credit Agreement, including maturity dates, payment and interest terms, please see Note (6) to the accompanying Condensed Consolidated Financial Statements, “Notes Payable and Credit Agreement.”


Letters of Credit
29

At
September 30, 2019, we maintained outstanding standby letters of credit totaling $17.1 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $17.1 million of outstanding letters of credit, we have collateralized $2.3 million in cash and cash equivalents and the remaining $14.8 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2018 totaled $17.6 million.
4.625% Senior Notes Due 2027

On October 1, 2019,August 13, 2020, AMN Healthcare, Inc. (the “Issuer”), a wholly owned subsidiary of AMN Healthcare Services, Inc. (the “Parent”),the Company, completed the issuance of an additional $200.0 million aggregate principal amount of 4.625% senior notes due 2027 (the “New 2027 Notes”), which were issued at a price of 101.000% of the aggregate principal amount. The New 2027 Notes were issued pursuant to the existing indenture, dated as of October 1, 2019, under which we previously issued $300.0 million aggregate principal amount of 4.625% Senior Notessenior notes due 2027 (the “Existing 2027 Notes” and together with the New 2027 Notes, the “2027 Notes”). The New 2027 Notes will mature on October 1, 2027.be treated as a single series with the Existing 2027 Notes and will have the same terms (other than issue price, issue date and the date from which interest accrues) as those of the Existing 2027 Notes. Interest on the 2027 Notes is payable semi-annually in arrears on April 1 and October 1 of each year, commencing AprilOctober 1, 2020 with respect to the New 2027 Notes. The terms of the Existing 2027 Notes, including maturity date, redemption and interest terms, are described in further detail in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—4.625% Senior Notes Due 2027” of our 2019 Annual Report.

We used the proceeds from the issuance of the New 2027 Notes to repay $200.0 million of our indebtedness under the Additional Term Loan during the third quarter of 2020.
The 2027
4.000% Senior Notes were issued pursuant to an Indenture (the “Indenture”)Due 2029

On October 20, 2020, AMN Healthcare, Inc., dated as of October 1, 2019, by and among the Issuer, the Parent, thea wholly owned subsidiary guarantors party thereto (collectively, together with the Parent, the “Guarantors”) and U.S. Bank National Association, as trustee, and are senior unsecured obligations of the Issuer.Company, completed the issuance of $350.0 million aggregate principal amount of 4.000% Senior Notes due 2029 (the “2029 Notes”). The Guarantors have guaranteed (the “Guarantees”) the Issuer’s obligations under the 2027 Notes and the Indenture on a senior unsecured basis. The Guarantors include the Parent and the subsidiaries of the Issuer that guarantee the Issuer’s Credit Facilities.
The 20272029 Notes will rank pari passu in right of payment with all ofmature on April 15, 2029. Interest on the Issuer’s existing and future senior indebtedness, senior to all of the Issuer’s existing and future subordinated indebtedness and effectively subordinated to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.
The Guarantees2029 Notes will be payable semi-annually in arrears on April 15 and October 15 of each Guarantor’s senior unsecured obligations and will rank pari passu in right of payment with all of such Guarantor’s existing and future senior indebtedness, senior to all of such Guarantor’s existing and future subordinated indebtedness and effectively subordinated to all of such Guarantor’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.year, commencing April 15, 2021.
The 2027 Notes and the Guarantees will be structurally subordinated to all existing and future indebtedness and other liabilities and preferred stock of any of the Issuer’s subsidiaries that do not guarantee the 2027 Notes.
At any time and from time to time on and after October 1, 2022, the IssuerApril 15, 2024, we will be entitled at itsour option to redeem all or a portion of the 20272029 Notes upon not less than 3010 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount on the redemption date) set forth below, plus accrued and unpaid interest, if any, to (but excluding) the redemption date (subject to the right of holders of record of the 20272029 Notes on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the twelve month period commencing on October 1April 15 of the years set forth below:

Period
Redemption
Price
2022 102.313%
2023 101.156%
2024 and thereafter 100.000%
PeriodRedemption
Price
2024102.000 %
2025101.000 %
2026 and thereafter100.000 %

At any time and from time to time prior to October 1, 2022, the IssuerApril 15, 2024, we may also redeem 20272029 Notes with the net cash proceeds of certain equity offerings in an aggregate principal amount not to exceed 40% of the aggregate principal amount of the 20272029 Notes issued, at a redemption price (expressed as a percentage of principal amount) of 104.625%104.000% of the principal amount thereof plus accrued and unpaid interest, if any, to (but excluding) the applicable redemption date.

In addition, the Issuerwe may redeem some or all of the 20272029 Notes at any time and from time to time prior to October 1, 2022April 15, 2024 at a redemption price equal to 100% of the principal amount of the 20272029 Notes redeemed, plus accrued and unpaid interest thereon, if any, to (but excluding) the applicable redemption date, plus a “make-whole” premium based on the applicable treasury rate plus 50 basis points.

Upon the occurrence of specified change of control events as defined in the Indenture,indenture governing the Issuer2029 Notes, we must offer to repurchase the 20272029 Notes at 101% of the principal amount, plus accrued and unpaid interest, if any, to (but excluding) the purchase date.

The Indentureindenture governing the 2029 Notes contains covenants that, among other things, restrict therestricts our ability of the Parent, the Issuer, and their restricted subsidiaries to:


sell assets,assets;
pay dividends or make other distributions on capital stock, make payments in respect of subordinated indebtedness or make other restricted payments,payments;
make certain investments,investments;
incur or guarantee additional indebtedness or issue preferred stock,stock;
create certain liens,liens;
30


enter into agreements that restrict dividends or other payments from restricted subsidiaries’ to the Issuer, the Parent or theirour restricted subsidiaries to us;
consolidate, merge or transfer all or substantially all of their assets,assets;
enter into transactions with affiliates,affiliates; and
create unrestricted subsidiaries.

These covenants are subject to a number of important exceptions and qualifications. The Indentureindenture governing the 2029 Notes contains affirmative covenants and events of default that are customary for Indenturesindentures governing high yield securities. The 20272029 Notes and the Guaranteesguarantees are not subject to any registration rights agreement.

We used the proceeds from the issuance of the 20272029 Notes, along with cash generated from operations, to (1) repay $149.1 millionredeem all of our existing Term Loan indebtedness,outstanding $325.0 million aggregate principal amount of 2024 Notes on November 4, 2020, (2) pay the associated redemption premium and all accrued and unpaid interest on the 2024 Notes, (3) repay $146.0$40.0 million under the Senior Credit Facility, and (3)(4) pay fees and expenses related to the offeringtransaction.
Letters of Credit
At September 30, 2020, we maintained outstanding standby letters of credit totaling $24.1 million as collateral in relation to our workers’ compensation insurance agreements and salea corporate office lease agreement. Of the $24.1 million of outstanding letters of credit, we have collateralized $2.2 million in cash and cash equivalents and the 2027 Notes.remaining $21.9 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2019 totaled $19.8 million.

Off-Balance Sheet Arrangements
At September 30, 2019,2020, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.
Contractual Obligations
There have been no material changes during the nine months ended September 30, 2019,2020, other than the borrowings and repayments under the NewAmended Credit Agreement and Amended Credit Agreementthe issuance the New 2027 Notes, which are described in the accompanying Note (2), “Acquisitions” and Note (6), “Notes Payable and Credit Agreement,” to the table entitled “Contractual Obligations” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in our 20182019 Annual Report.

Recent Accounting Pronouncements
In June 2016,December 2019, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.2019-12, “Simplifying the Accounting for Income Taxes.” The standard introducesis expected to reduce cost and complexity related to accounting for income taxes. The new accounting models for determining and recognizing credit losses on certain financial instruments based on an estimate of current expected credit losses and is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We are in the process of analyzing the requirements of this standard and evaluating the impact on our consolidated financial statements. This includes reviewing current accounting policies and practices to identify potential differences that would result from applying the requirements under the new standard. We completed our preliminary assessment and expect to complete the evaluation of the impact of the accounting and disclosure requirements on our business processes, controls and systems by the end of 2019. We will adopt this standard in the first quarter of 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for anycertain exceptions and clarifies and amends existing guidance to promote consistent application among reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test.entities. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019, with early adoption permitted for impairment tests performed after January 1, 2017. We will adopt this standard in the first quarter of 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The standard modifies the current disclosure requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019.2020, with early adoption permitted. Depending on the amendment, adoption may be applied on a retrospective, modified retrospective or prospective basis. We will adopt this standard in the first quarter of 2020 and are currently evaluating the effect thatimpact of adopting it will havethis standard on our disclosures.consolidated financial statements.
In August 2018,January 2020, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The standard aligns2020-01, “Clarifying the requirements for capitalizing implementation costs incurred in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.Interactions between Topic 321, Topic 323, and Topic 815.” The new guidance requiresclarifies the capitalized implementation costsinteractions between accounting standards that apply to be recorded as an other asset, rather than a fixed asset,equity investments without readily determinable fair values. Specifically, it addresses the accounting for the transition into and out of the related amortization of those costs to be recorded in selling, general and administrative expenses.equity method. This standard is effective on a prospective or retrospective basis for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019,2020, with early adoption permitted. We will adoptare currently evaluating the effect of adopting this standard prospectively in the first quarter of 2020 andon our consolidated financial statements, but do not expect the adoption to have a material impact on our consolidated financial statements.impact.
There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.
31


Special Note Regarding Forward-Looking Statements
This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 20182019 Annual Report and include but are not limited to:
the effects of the COVID-19 pandemic on our business, financial condition and results of operations;
the duration and extent to which hospitals and other healthcare entities decrease their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the suspension or reinstitution of restrictions placed on non-essential and elective healthcare as a result of the COVID-19 pandemic;
the duration that individuals may continue to forgo non-essential and elective healthcare as “safer at home” restrictions and recommendations are reinstituted in parts of the country and lifted in others;
the extent and duration that a significant spike in unemployment that has resulted from the COVID-19 pandemic will cause an increase in under- and uninsured patients and a corresponding reduction in overall healthcare utilization and demand for our services;
the extent to which the COVID-19 pandemic may disrupt our operations due to the unavailability of our employees or healthcare professionals due to illness, risk of illness, quarantines, travel restrictions, desire to travel and work on temporary assignments or other factors that limit our existing or potential workforce and pool of candidates;
the severity and duration of the impact the COVID-19 pandemic has on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered;
the effects of economic downturns or slow recoveries, which could result in less demand for our services, pricing pressures and pricing pressures;negatively impact payments terms and collectability of accounts receivable;
any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs;
the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts with our clients;contracts;
the level of consolidation and concentration of buyers of healthcare workforce, solutionsstaffing and staffing services,technology solutions, which could affect the pricing of our services and our ability to mitigate concentration risk;
the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, telemedicine or otherwise, which may negatively affect our revenue, results of operations, and cash flows;
the repeal or significant erosion of the Patient Protection and Affordable Care Act without a corresponding replacement may negatively affect the demand for our services;
any inability on our part to grow and operate our business profitably in compliance with federal and state healthcare industry regulation, including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting; 
any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;

any inability on our part to grow and operate our business profitably in compliance with federal and state regulation, including privacy laws, conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting; 
32


any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
the effect of investigations, claims, and legal proceedings alleging medical malpractice, violations of employment, privacy and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and ability to manage our business effectively;
any failure to further develop and evolve our current workforce solutions technology offerings and capabilities, which may harm our business;
disruption to or failures of our SaaS-based technology, or our inability to adequately protect our intellectual property rights with respect to such technology, sufficiently protect the privacy of personal information, which could reduce client satisfaction, harm our reputation and negatively affect our business;
security breaches and cybersecurity incidents that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities;
any inability on our part to quickly and properly credential and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;
any inability on our part to continue to attract, develop and retain our sales and operations team members, which may deteriorate our operations;
our increasing dependence on third parties, including offshore vendors, for the execution of certain critical functions;
the loss of our key officers and management personnel, which could adversely affect our business and operating results;
any inability to consummate and effectively incorporate acquisitions into our business operations, which may adversely affect our long-term growth and our results of operations;
businesses we acquire may have liabilities or adverse operating issues, which could harm our operating results;
any increase to our business and operating risks as we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of client solutions;
any inability on our part to maintain our positive brand awareness and identity, which may adversely affect our results of operation;
the expansion of social media platforms presents new risks and challenges, which could cause damage to our brand reputation;
any recognition of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;
our indebtedness, which could adversely affect our ability to raise additional capital to fund operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt;
the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and
the effect of significant adverse adjustments to our insurance-related accruals on our balance sheet, which could decrease our earnings or increase our losses and negatively impact our cash flows.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and nine months ended September 30, 2019,2020, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2019. On October 1, 2019, we completed the issuance of $300.0 million aggregate principal amount of the 2027 Notes. With the proceeds from the issuance of the 2027 Notes, we repaid the full existing balance under the Senior Credit Facility and the full outstanding balance under the term loan indebtedness.2020. During the three and nine months ended September 30, 2019,2020, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.
33


Item 4. Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 20192020 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
 
There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 20192020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
34




PART II - OTHER INFORMATION
 
Item 1. Legal Proceedings
None.

Item 1A. Risk Factors
We do not believe that, there have been any material changesin addition to the risk factors disclosed in Part I, Item 1A of our 20182019 Annual Report, the following risks could materially adversely affect our business or our consolidated operating results, financial condition or cash flows, which, in turn, could cause the price of our common stock to decline. The risk factors described below and in our 2019 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows. The risk factors described below qualify all forward-looking statements we make, including forward-looking statements within the section entitled “Risk Factors” in Part I, Item 1A of our 2019 Annual Report.

The widespread outbreak of illness or other public health crisis could have an adverse effect on our business, financial condition and results of operations.

We could be negatively affected by the widespread outbreak of an illness or any other public health crisis. The COVID-19 pandemic has negatively impacted the global economy and created significant volatility and disruption of financial markets.There remains a significant risk that the “shelter-in-place” orders, quarantines and restrictions on travel and mass gatherings that were ordered earlier in the year to slow the spread of the virus may be reinstituted as COVID-19 rates continue to climb in many parts of the country. In addition, many “non-essential” businesses continue to restrict their operations or shift to a remote working environment, which restricts the delivery of non-emergency healthcare.

Demand for our staffing services and workforce technology solutions is sensitive to changes in economic activity and has fluctuated significantly over the course of the COVID-10 pandemic. Demand for non-essential and elective healthcare has been negatively impacted by the COVID-19 pandemic. Many hospitals and other healthcare entities have significantly decreased their utilization of temporary healthcare professionals, interpreters, coders and permanent recruitment and placement services, which has resulted in decreased demand for many of our service offerings and utilization of our workforce technology platforms. We expect this decreased demand will have an adverse effect on our business, financial condition and results of operations. Many individuals may continue to forgo non-essential and elective healthcare even after “safer at home” restrictions and recommendations are lifted. We are unable to predict the duration and extent to which demand for our services will be negatively impacted by the COVID-19 pandemic.
In addition, the significant spike in unemployment that has resulted from the COVID-19 pandemic will likely cause an increase in under- and uninsured patients, which generally results in a reduction in overall healthcare utilization and a decrease in demand for our services. At this time, we are unable to predict the duration and extent to which our businesses will be negatively impacted by the increased unemployment and under- and uninsured rates resulting from the COVID-19 pandemic.
The COVID-19 pandemic, and any other outbreak of illness or other public health crises, may also disrupt our operations due to the unavailability of our corporate team members or healthcare professionals due to illness, risk of illness, quarantines, travel restrictions or other factors that limit our existing or potential workforce and pool of candidates. In addition, we may experience negative financial effects of the COVID-19 due to higher workers’ compensation and health insurance costs, for which we are largely self-insured. We may also be subject to claims regarding the health and safety of our healthcare professionals and our corporate team members.
Given the economic impact the COVID-19 pandemic has had on the financial condition of many hospitals and healthcare systems, many of our clients have experienced cash flow issues and difficulty gaining access to sufficient credit, which has, in some cases, impaired their ability to make payments to us, timely or otherwise, for services rendered and we have already experienced an increase to our allowance for credit losses for accounts receivable. We may also be subject to claims from these clients relating to the ability to provide services under terms and conditions that they believe are fair and reasonable.

The foregoing and other continued disruptions to our business as a result of COVID-19 could have an adverse effect on our business, financial condition and results of operations. The extent of the impact of COVID-19 on our operational and financial performance will depend on future developments, including the duration and spread of the COVID-19 outbreak, which is highly uncertain and cannot be predicted at this time.

35


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

From time to time, we may repurchase our common stock in the open market pursuant to programs approved by our Board. We may repurchase our common stock for a variety of reasons, such as acquiring shares to offset dilution related to equity-based incentives and optimizing our capital structure. On November 1, 2016, our Board authorized us to repurchase up to $150.0 million of our outstanding common stock in the open market. Under the repurchase program announced on November 1, 2016 (the “Company Repurchase Program”), share purchases may be made from time to time beginning in the fourth quarter of 2016, depending on prevailing market conditions and other considerations. The Company Repurchase Program has no expiration date and may be discontinued or suspended at any time.

During the nine months ended September 30, 2019,2020, we purchased 395,212did not repurchase any shares of common stock at an average price of $47.30 per share, resultingstock. We describe in an aggregate purchase price of $18.7 million. The following table presentsfurther detail our repurchase program and the detail of shares repurchased during the nine months ended September 30, 2019. All share repurchases reflectedthereunder in the table below were made under the Company Repurchase Program, which is the sole repurchase programPart II, Item 5, “Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of the Company currentlyEquity Securities” set forth in effect.our 2019 Annual Report.

     
Period
 
Total
Number of
Shares (or
Units)
Purchased 
 
Average
Price Paid
per Share
(or Unit) 
 
Total Number of
Shares (or Units)
Purchased as Part of
Publicly Announced
Program 
 
Maximum Dollar
Value of Shares (or Units)
that May Yet Be
Purchased Under the Program 
 
February 1 - 28, 201922,900
$50.5022,900
$48,405,129
March 1 - 31, 2019355,417
$47.16355,417
$31,631,647
April 1 - 30, 201916,895
$45.8016,895
$30,857,280
  
  
 
Total395,212
$47.30395,212
$30,857,280

Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
Not applicable.

Item 5. Other Information
None.

36



Item 6. Exhibits
 
Exhibit
Number
Description
4.1
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document.*
101.SCHXBRL Taxonomy Extension Schema Document.*
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.*
101.LABXBRL Taxonomy Extension Label Linkbase Document.*
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.*
*Filed herewith.
*Filed herewith.
37


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 4, 2019
Date: November 6, 2020
AMN HEALTHCARE SERVICES, INC.
/S/    SUSAN R. SALKA
Susan R. Salka

President and Chief Executive Officer

(Principal Executive Officer)

 
Date: November 4, 20196, 2020

 

/S/    BRIAN M. SCOTT
Brian M. Scott

Chief Accounting Officer,

Chief Financial Officer and Treasurer

(Principal Accounting and Financial Officer)

3438